{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# NetworkX exercise "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "%matplotlib inline\n",
    "import networkx as nx\n",
    "import vis_bel\n",
    "import os\n",
    "import pickle\n",
    "import imp\n",
    "import numpy as np\n",
    "import itertools as itt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "base = os.environ['BUG_FREE_EUREKA_BASE']\n",
    "path_networkx_AD_pickled =os.path.join(base,'data','exercise05','networkx.graph.AD.pickled')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Loading Alzheimer's disease network into networkX graph with pickle"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "graph_AD = pickle.load(open(path_networkx_AD_pickled,'rb'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "networkx.classes.multidigraph.MultiDiGraph"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(graph_AD)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Here some words about [pickle](https://docs.python.org/3/library/pickle.html)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Explore"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(11927, 11927, 11927)"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(graph_AD), len(graph_AD.nodes()), graph_AD.number_of_nodes()  # number of nodes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "59408"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_AD.number_of_edges() # number of nodes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{2: {0: {'Subgraph': ('Non-amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('Other', 'Connectors', '123'),\n",
       "   'evidence': 'The statements inside this citation is included to connect two entity types or triples, which will exist as islands/subnetworks in the big model.',\n",
       "   'object_activity': 'act',\n",
       "   'rel': 'decreases'},\n",
       "  1: {'DiseaseState': ('Mild AD',),\n",
       "   'FDASTATUS': ('Phase 3',),\n",
       "   'Subgraph': ('Notch pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'Curr Med Chem. 2011;18(35):5430-47', '22087836'),\n",
       "   'evidence': 'gamma-Secretase inhibitor believed to be associated with the inhibition of the cleavage of Notch, a transmembrane receptor involved in regulating cell-fate decisions.',\n",
       "   'object_activity': 'pep',\n",
       "   'rel': 'decreases'}},\n",
       " 1828: {0: {'DiseaseState': ('Mild AD',),\n",
       "   'FDASTATUS': ('Phase 3',),\n",
       "   'Subgraph': ('Notch pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'Curr Med Chem. 2011;18(35):5430-47', '22087836'),\n",
       "   'evidence': 'gamma-Secretase inhibitor believed to be associated with the inhibition of the cleavage of Notch, a transmembrane receptor involved in regulating cell-fate decisions.',\n",
       "   'rel': 'decreases'}}}"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_AD[1] # node 1 connections with edge information"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys([2, 1828])"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_AD[1].keys() # nodes ids connected to node 1 "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys([0, 1])"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_AD[1][2].keys()\n",
    "# edge between these both"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Subgraph': ('Non-amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       " 'citation': ('Other', 'Connectors', '123'),\n",
       " 'evidence': 'The statements inside this citation is included to connect two entity types or triples, which will exist as islands/subnetworks in the big model.',\n",
       " 'object_activity': 'act',\n",
       " 'rel': 'decreases'}"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_AD[1][2][0].keys()\n",
    "graph_AD[1][2][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'decreases'"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_AD[1][2][0].get('rel')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[1, 2]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_AD.nodes()[:2] # all nodes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(1,\n",
       "  {'BEL': 'a(CHEBI:\"gamma-secretase inhibitor\")',\n",
       "   'function': 'a',\n",
       "   'namespace': 'CHEBI',\n",
       "   'value': 'gamma-secretase inhibitor'}),\n",
       " (2,\n",
       "  {'BEL': 'complex(SCOMP:\"gamma Secretase Complex\")',\n",
       "   'function': 'complex',\n",
       "   'namespace': 'SCOMP',\n",
       "   'value': '\"gamma Secretase Complex\"'})]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_AD.nodes(data=True)[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(1, 2), (1, 2)]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_AD.edges()[:2]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(1,\n",
       "  2,\n",
       "  0,\n",
       "  {'Subgraph': ('Non-amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('Other', 'Connectors', '123'),\n",
       "   'evidence': 'The statements inside this citation is included to connect two entity types or triples, which will exist as islands/subnetworks in the big model.',\n",
       "   'object_activity': 'act',\n",
       "   'rel': 'decreases'}),\n",
       " (1,\n",
       "  2,\n",
       "  1,\n",
       "  {'DiseaseState': ('Mild AD',),\n",
       "   'FDASTATUS': ('Phase 3',),\n",
       "   'Subgraph': ('Notch pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'Curr Med Chem. 2011;18(35):5430-47', '22087836'),\n",
       "   'evidence': 'gamma-Secretase inhibitor believed to be associated with the inhibition of the cleavage of Notch, a transmembrane receptor involved in regulating cell-fate decisions.',\n",
       "   'object_activity': 'pep',\n",
       "   'rel': 'decreases'})]"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_AD.edges(data=True,keys=True)[:2]\n",
    "# keys => number of edges inside "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "```\n",
    "[(1, \n",
    "  2,\n",
    "  0, <- index of the edge\n",
    "```"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "#nodes = np.random.choice(graph,size=100,replace=False)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "nodes = set(itt.chain.from_iterable((formN,toN) for formN,toN  in graph_AD.edges()[:100]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "graph_100 = graph_AD.subgraph(nodes)\n",
    "# creating a subgraph "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAeIAAAFBCAYAAACrYazjAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x10f7c1f28>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "nx.draw(graph_100)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAeIAAAFBCAYAAACrYazjAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x1044839e8>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "nx.draw_spring(graph_100, with_labels=True)\n",
    "# delegates everything to the draw function\n",
    "\n",
    "# "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAeIAAAFBCAYAAACrYazjAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nAAAAAElFTkSuQmCC\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x10e254dd8>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "nx.draw_spectral(graph_100)\n",
    "# eigenvalues"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "collapsed": false,
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "        <iframe\n",
       "            width=\"1000\"\n",
       "            height=\"800\"\n",
       "            src=\"graph-temp.html\"\n",
       "            frameborder=\"0\"\n",
       "            allowfullscreen\n",
       "        ></iframe>\n",
       "        "
      ],
      "text/plain": [
       "<IPython.lib.display.IFrame at 0x10e30ca90>"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "imp.reload(vis_bel)\n",
    "vis_bel.draw(graph_100)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(1, 2, 0, {'Subgraph': ('Non-amyloidogenic pathway', 'Gamma secretase pathway'), 'evidence': 'The statements inside this citation is included to connect two entity types or triples, which will exist as islands/subnetworks in the big model.', 'object_activity': 'act', 'citation': ('Other', 'Connectors', '123'), 'rel': 'decreases'})\n"
     ]
    }
   ],
   "source": [
    "for edge in graph_100.edges_iter(data=True,keys=True):\n",
    "    print(edge)\n",
    "    break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1 2 0 {'Subgraph': ('Non-amyloidogenic pathway', 'Gamma secretase pathway'), 'evidence': 'The statements inside this citation is included to connect two entity types or triples, which will exist as islands/subnetworks in the big model.', 'object_activity': 'act', 'citation': ('Other', 'Connectors', '123'), 'rel': 'decreases'}\n"
     ]
    }
   ],
   "source": [
    "for u,v,k,a in graph_100.edges_iter(data=True,keys=True):\n",
    "    print(u,v,k,a)\n",
    "    break"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Tasks\n",
    "\n",
    "0. Find the node with the highest degree in graph_100\n",
    "0. get all distinct attribute keys in nodes and edges for graph_100\n",
    "0. Write a function which allows you to search all edges in the graph_100 with any key (or key/value). Allow value to be optional\n",
    "0. Find shortest paths between all nodes link to the edges found in the previsious task and create a new graph, display it "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Task 1: Find the node with the highest degree in graph_100"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "6"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import operator\n",
    "max(graph_100.degree().items(), key=operator.itemgetter(1))[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "6"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dct_graph = graph_100.degree()\n",
    "max(dct_graph, key=dct_graph.get)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {
    "collapsed": false,
    "scrolled": false
   },
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "'dict' object is not callable",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-50-c15240ef81f9>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mdct_graph\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mdata\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mTrue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m5\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mTypeError\u001b[0m: 'dict' object is not callable"
     ]
    }
   ],
   "source": [
    "graph_100.nodes(data=True)[5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Task 2: Get all distinct attribute keys in nodes and edges for graph_100"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {
    "collapsed": false,
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['value', 'namespace', 'function', 'BEL', 'valid_NSV', 'list']"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "distinct_nodes_attr = []\n",
    "for item in graph_100.nodes(data=True):\n",
    "    for attr in item[1].keys():\n",
    "        if attr not in distinct_nodes_attr:\n",
    "            distinct_nodes_attr.append(attr)\n",
    "distinct_nodes_attr"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Subgraph',\n",
       " 'evidence',\n",
       " 'object_activity',\n",
       " 'citation',\n",
       " 'rel',\n",
       " 'FDASTATUS',\n",
       " 'DiseaseState',\n",
       " 'subject_activity',\n",
       " 'FluidAndSecretion',\n",
       " 'CellStructure',\n",
       " 'NervousSystem',\n",
       " 'MeSHDisease',\n",
       " 'UserdefinedCellLine',\n",
       " 'DigestiveSystem',\n",
       " 'Species',\n",
       " 'Cell',\n",
       " 'subject_translocation_from_namespace',\n",
       " 'subject_translocation_from_value',\n",
       " 'subject_translocation_to_namespace',\n",
       " 'subject_translocation',\n",
       " 'subject_translocation_to_value',\n",
       " 'UserdefinedSpecies',\n",
       " 'CellLine',\n",
       " 'UserdefinedGender',\n",
       " 'Duration_of_Chemical_Exposure',\n",
       " 'Encode_Feature_Types',\n",
       " 'Developmental_Phase__of_patient',\n",
       " 'object_translocation_from_value',\n",
       " 'object_translocation_to_value',\n",
       " 'object_translocation',\n",
       " 'object_translocation_to_namespace',\n",
       " 'object_translocation_from_namespace',\n",
       " 'CardiovascularSystem',\n",
       " 'Tissue']"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "distinct_edges_attr = []\n",
    "for item in graph_100.edges(data=True):\n",
    "    for attr in item[2].keys():\n",
    "        if attr not in distinct_edges_attr:\n",
    "            distinct_edges_attr.append(attr)\n",
    "distinct_edges_attr"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Task 3: Write a function which allows you to search all edges in the graph_100 with any key (or key/value). Allow value to be optional"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**hint** : Write a function which allows you to search all edges in the graph_100 with any key (or key/value). Allow value to be optional"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {
    "collapsed": false,
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(2,\n",
       "  2212,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Phosphatidylinositol 3 pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurochem. 2007 Aug;102(3):848-57. Epub 2007 Apr 16',\n",
       "    '17437536'),\n",
       "   'evidence': \"We previously showed that some familial Alzheimer's disease PS mutations cause increased basal and acetylcholine muscarinic receptor-stimulated phospholipase C (PLC) activity which was gamma-secretase dependent.\",\n",
       "   'rel': 'association'}),\n",
       " (2,\n",
       "  7,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Phosphatidylinositol 3 pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurochem. 2007 Aug;102(3):848-57. Epub 2007 Apr 16',\n",
       "    '17437536'),\n",
       "   'evidence': \"We previously showed that some familial Alzheimer's disease PS mutations cause increased basal and acetylcholine muscarinic receptor-stimulated phospholipase C (PLC) activity which was gamma-secretase dependent.\",\n",
       "   'rel': 'association'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'NervousSystem': ('Central Nervous System',),\n",
       "   'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Biol Psychiatry. 2013 Sep 1;74(5):357-66',\n",
       "    '23312564'),\n",
       "   'evidence': 'Hence, mifepristone induces a novel C-terminal cleavage of APP that prevents it being cleaved by - or -secretase, thereby precluding A generation in the central nervous system; this cleavage and the production of the 17-kDa APP fragment was generated by a calcium-dependent cysteine protease.',\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  5,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Species': ('9606',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': 'BACE1 cleaves -amyloid precursor protein (APP) to generate amyloid  protein (A), a central component of neuritic plaques in AD brains.',\n",
       "   'rel': 'association'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Pharm Pharmacol. 2011 Aug;63(8):1111-8',\n",
       "    '21718295'),\n",
       "   'evidence': \"Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.\",\n",
       "   'rel': 'negativeCorrelation'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Pharm Pharmacol. 2011 Aug;63(8):1111-8',\n",
       "    '21718295'),\n",
       "   'evidence': \"In this study, we aimed to investigate the possibility of P-gp as a potential therapeutic target for Alzheimer's disease by examining the impact of P-gp up-regulation on the clearance of A, a neuropathological hallmark of Alzheimer's disease.Uptake studies for-radiolabelled A Approximately 10-35% decrease in A intracellular accumulation was observed in cells treated with rifampicin, dexamethasone, caffeine, verapamil, hyperforin, -estradiol and pentylenetetrazole compared with control.\",\n",
       "   'rel': 'decreases'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Pharm Pharmacol. 2011 Aug;63(8):1111-8',\n",
       "    '21718295'),\n",
       "   'evidence': 'Also, fluorescent micrographs showed an inverse relationship between levels of P-gp expression and 5-carboxyfluorescein labelled A (FAM-A42) intracellular accumulation.',\n",
       "   'rel': 'negativeCorrelation'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Nuclear factor Kappa beta pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': \"Increased NF-B signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.\",\n",
       "   'rel': 'association'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Species': ('9606',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Nuclear factor Kappa beta pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': \"Elevated levels of -site APP cleaving enzyme 1 (BACE1) were found in the brain of some sporadic Alzheimer's disease (AD) patients; however, the underlying mechanism is unknown.\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed', 'J Med Chem. 2012 Nov 8;55(21):9224-39', '22984865'),\n",
       "   'evidence': \"-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (5,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Species': ('9606',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': 'BACE1 cleaves -amyloid precursor protein (APP) to generate amyloid  protein (A), a central component of neuritic plaques in AD brains.',\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Pharm Pharmacol. 2011 Aug;63(8):1111-8',\n",
       "    '21718295'),\n",
       "   'evidence': \"Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.\",\n",
       "   'rel': 'negativeCorrelation'}),\n",
       " (6,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Pharm Pharmacol. 2011 Aug;63(8):1111-8',\n",
       "    '21718295'),\n",
       "   'evidence': 'Also, fluorescent micrographs showed an inverse relationship between levels of P-gp expression and 5-carboxyfluorescein labelled A (FAM-A42) intracellular accumulation.',\n",
       "   'rel': 'negativeCorrelation'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'CardiovascularSystem': ('Microvessels',),\n",
       "   'MeSHDisease': ('Hypertension',\n",
       "    'Alzheimer Disease',\n",
       "    'Cerebral Amyloid Angiopathy'),\n",
       "   'NervousSystem': ('Cerebrum',),\n",
       "   'Subgraph': ('Nitric oxide pathway', 'Non-amyloidogenic pathway'),\n",
       "   'Tissue': ('Endothelium',),\n",
       "   'citation': ('PubMed', 'Med Hypotheses. 2014 Feb;82(2):145-50', '24332564'),\n",
       "   'evidence': 'First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.',\n",
       "   'rel': 'increases'}),\n",
       " (2212,\n",
       "  2,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Phosphatidylinositol 3 pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurochem. 2007 Aug;102(3):848-57. Epub 2007 Apr 16',\n",
       "    '17437536'),\n",
       "   'evidence': \"We previously showed that some familial Alzheimer's disease PS mutations cause increased basal and acetylcholine muscarinic receptor-stimulated phospholipase C (PLC) activity which was gamma-secretase dependent.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  2,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Phosphatidylinositol 3 pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurochem. 2007 Aug;102(3):848-57. Epub 2007 Apr 16',\n",
       "    '17437536'),\n",
       "   'evidence': \"We previously showed that some familial Alzheimer's disease PS mutations cause increased basal and acetylcholine muscarinic receptor-stimulated phospholipase C (PLC) activity which was gamma-secretase dependent.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Nuclear factor Kappa beta pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': \"Increased NF-B signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Species': ('9606',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Nuclear factor Kappa beta pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': \"Elevated levels of -site APP cleaving enzyme 1 (BACE1) were found in the brain of some sporadic Alzheimer's disease (AD) patients; however, the underlying mechanism is unknown.\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed', 'J Med Chem. 2012 Nov 8;55(21):9224-39', '22984865'),\n",
       "   'evidence': \"-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'})]"
      ]
     },
     "execution_count": 120,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def find_edges_by_attrib_key_value(graph, attribKey, attribValue=None):\n",
    "    edge_list = []\n",
    "    if attribValue is None:\n",
    "        for item in graph_100.edges(data=True):\n",
    "                if attribKey in item[2]:\n",
    "                    edge_list.append(item)\n",
    "    else:            \n",
    "        for item in graph_100.edges(data=True):\n",
    "            if attribKey in item[2]:\n",
    "                if attribValue in item[2][attribKey]:\n",
    "                    edge_list.append(item)                    \n",
    "    return edge_list if edge_list else False\n",
    "\n",
    "# find_edges_by_attrib_key_value(graph_100, 'MeSHDisease')\n",
    "find_edges_by_attrib_key_value(graph_100, 'MeSHDisease', 'Alzheimer Disease')\n",
    "# find_edges_by_attrib_key_value(graph_100, 'Subgraph')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(1,\n",
       "  2,\n",
       "  {'Subgraph': ('Non-amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('Other', 'Connectors', '123'),\n",
       "   'evidence': 'The statements inside this citation is included to connect two entity types or triples, which will exist as islands/subnetworks in the big model.',\n",
       "   'object_activity': 'act',\n",
       "   'rel': 'decreases'}),\n",
       " (1,\n",
       "  2,\n",
       "  {'DiseaseState': ('Mild AD',),\n",
       "   'FDASTATUS': ('Phase 3',),\n",
       "   'Subgraph': ('Notch pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'Curr Med Chem. 2011;18(35):5430-47', '22087836'),\n",
       "   'evidence': 'gamma-Secretase inhibitor believed to be associated with the inhibition of the cleavage of Notch, a transmembrane receptor involved in regulating cell-fate decisions.',\n",
       "   'object_activity': 'pep',\n",
       "   'rel': 'decreases'}),\n",
       " (1,\n",
       "  1828,\n",
       "  {'DiseaseState': ('Mild AD',),\n",
       "   'FDASTATUS': ('Phase 3',),\n",
       "   'Subgraph': ('Notch pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'Curr Med Chem. 2011;18(35):5430-47', '22087836'),\n",
       "   'evidence': 'gamma-Secretase inhibitor believed to be associated with the inhibition of the cleavage of Notch, a transmembrane receptor involved in regulating cell-fate decisions.',\n",
       "   'rel': 'decreases'}),\n",
       " (2,\n",
       "  1537,\n",
       "  {'Subgraph': ('Gamma secretase pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Neurosci Lett. 2013 Aug 26;548:90-4. doi: 10.1016/j.neulet.2013.05.018. Epub 2013 May 15.',\n",
       "    '23685131'),\n",
       "   'evidence': 'The -secretase complex comprises presenilins (PS1 or PS2), nicastrin, APH-1, and PEN-2. Herein, we find that PEN-2 can interact with ferritin light chain (FTL), an important component of the iron storage protein ferritin. In addition, we show that overexpression of FTL increases the protein levels of PEN-2 and PS1 amino-terminal fragment (NTF) and promotes -secretase activity for more production of A and notch intracellular domain (NICD). Furthermore, iron treatments increase the levels of FTL, PEN-2 and PS1 NTF and promote -secretase-mediated NICD production. Moreover, downregulation of FTL decreases the levels of PEN-2 and PS1 NTF. Together, our results suggest that iron can increase -secretase activity through promoting the level of FTL that interacts with and stabilizes PEN-2, providing a new molecular link between iron, PEN-2/-secretase and A generation in AD.',\n",
       "   'rel': 'hasMembers'}),\n",
       " (2,\n",
       "  4,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': 'Processing of APP to produce Ab involves cleavage by b-site APP cleaving enzyme-1 (BACE1) and g-secretase that process APP at the N- and C-termini, respectively, of the Ab sequence.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  4,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'BMC Neurol. 2012 Jun 15;12(1):38. [Epub ahead of print]',\n",
       "    '22702962'),\n",
       "   'evidence': 'Amyloid plaques consist primarily of amyloid  protein (A), which is produced when APP is cleaved by -secretase and then cleaved again by -secretase as part of the amyloidogenic pathway.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  4,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Clin Invest. 2004 Jul;114(1):23-7', '15232608'),\n",
       "   'evidence': 'A\\x9f is generated from APP by concerted proteolysis by \\x9f-secretase, which generates carboxyl-terminal fragments (CTFs) of APP, and then by gamma-secretase.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  4,\n",
       "  {'Subgraph': ('Gamma secretase pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    '2010 Apr 13;107(15):6557-8. doi: 10.1073/pnas.1002555107.',\n",
       "    '20385830'),\n",
       "   'evidence': 'The pathogenesis of AD begins with impaired synaptic function, which may result from the accumulation of amyloid-\\x8e (A\\x8e) peptide (5\\x828). For many years, researchers have focused on the insoluble deposits of amyloid fibrils as the leading cause of memory loss and as the culprit of AD. More recent findings, however, suggest soluble A\\x8e oligomers may be the cause of memory loss, especially in the early stages of AD, because A\\x8e oligomers inhibit long-term potentiation in neurons, a well-adopted experimental paradigm for learning and memory (6, 9). A\\x8e is produced from amyloid precursor protein (APP) by serial proteolytic reactions catalyzed by \\x8e-site of APP cleaving enzyme (BACE) and a multiprotein complex \\x8e-secretase, in which presenilin is likely the catalytic component ',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  4,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': 'Processing of APP to produce Ab involves cleavage by b-site APP cleaving enzyme-1 (BACE1) and g-secretase that process APP at the N- and C-termini, respectively, of the Ab sequence.',\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  4,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Cell Adh Migr. 2011 Jul-Aug;5(4):280-92. Epub 2011 Jul 1.',\n",
       "    '21785276'),\n",
       "   'evidence': 'The amyloid-beta (A\\x8e) peptide is the derivative of amyloid precursor protein (APP) generated through sequential proteolytic processing by \\x8e- and \\x8e-secretases. Excessive accumulation of A\\x8e, the main constituent of amyloid plaques, has been implicated in the etiology of Alzheimer disease (AD). ',\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'Notch pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'CNS Drugs. 2006;20(5):351-72.', '16696577'),\n",
       "   'evidence': \"gamma-Secretase comprises a molecular complex of four integral membrane proteins - presenilin, nicastrin, APH-1 and PEN-2 - and its molecular mechanism remains under extensive scrutiny. The ratio of Abeta(42) over Abeta(40) is increased by familial Alzheimer's disease mutations occurring in the presenilin genes or in APP, near the gamma-secretase cleavage site.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'G protein mediated pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Nat Med. 2013 Jan;19(1):22-4. doi: 10.1038/nm.3053.',\n",
       "    '23296004'),\n",
       "   'evidence': \"In this issue of Nature Medicine, Thathiah et al.4 now provide provocative evidence that the adaptor protein -arrestin 2 mediates the A-altering effects of these GPCRs by promoting A generation. This newly uncovered function of -arrestin 2 suggests it could be targeted to decrease amyloid pathology in patients with Alzheimer's disease. Production of the amyloid- peptide in Alzheimer's disease by the -secretase complex can be regulated by certain G protein\\x80\\x93coupled receptors. This regulation seems to be mediated by -arrestin-2, whose expression was found to be elevated in Alzheimer's disease brains.Recruitment of -arrestin 2 to a GPCR leads to interaction with the -secretase complex via the Aph-1 subunit. Other members of the complex include presenilin-1 (PS-1), nicastrin (Nct) and Pen-2. The complex then moves laterally into lipid rafts, where -secretase activation is enhanced. Internalization may also occur to localize -secretase to late endosomes, where its activation is also increased. Cleavage of APP by -secretase (BACE1) to release soluble APP (sAPPb) followed by -secretase produces A and APP intracellular domain (AICD). Increased production and secretion of A from cells can lead to extracellular A aggregation in the form of plaques. Mutagenesis of GPR3 in regions of the protein that specifically interact with either G protein or -arrestin 2 further showed that -arrestin 2, not G protein, mediates the ability of GPR3 to increase A levels.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2009 May 1;284(18):12145-52. doi: 10.1074/jbc.M808497200. Epub 2009 Mar 10.',\n",
       "    '19276086'),\n",
       "   'evidence': 'Moreover, we find that PLD1 also regulates PS1 trafficking and that PLD1 overexpression promotes cell surface accumulation of PS1 in an APP-independent manner. Our results clearly elucidate a physiological function of APP in regulating protein trafficking and suggest that intracellular trafficking of PS1/gamma-secretase is regulated by multiple factors, including APP and PLD1.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2008 Oct 31;283(44):29615-9. Epub 2008 Jul 23.',\n",
       "    '18650430'),\n",
       "   'evidence': 'Interestingly, Fe65 acts as a functional linker between APP and LRP (another type I membrane protein containing two NPXY endocytosis motifs) in modulating endocytic APP trafficking and A\\x9f production. A conformational change introduced by phosphorylation at Thr668 (14 amino acids proximal to the YENPTY motif) interferes with Fe65 binding to APP and facilitates BACE1 and gamma-secretase cleavage of APP.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'act'}),\n",
       " (2,\n",
       "  6,\n",
       "  {'FluidAndSecretion': ('Bodily Secretions',),\n",
       "   'Subgraph': ('Amyloidogenic pathway',\n",
       "    'Unfolded protein response',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Biochem Biophys Res Commun. 2011 Dec 16;416(3-4):362-6. doi: 10.1016/j.bbrc.2011.11.042. Epub 2011 Nov 16.',\n",
       "    '22115781'),\n",
       "   'evidence': 'In this study, we demonstrate that ER stress induces presenilin-1 expression through activating transcription factor 4 (ATF4), resulting in increased amyloid- (A) secretion by -secretase activity, which is suppressed by quercetin by modifying UPR signaling.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  263,\n",
       "  {'Subgraph': ('Notch pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Another relevant role for PSs is Notch processing. Notch signaling is involved in cell fate regulation, cell differentiation, proliferation, and apoptosis as well as neurodegeneration. Notch is a membrane receptor whose C-terminal domain (NICD), upon interaction with appropriate ligands, translocates into the nucleus where it activates the CSL family of transcription factors. NICD formation depends on gamma-secretase complex as the AICD fragment of A\\x9fPP. PSs play a role in apoptosis, since FAD mutants cause cell death or induce secondary events that may lead to apoptosis .Animals, in which PS1 and PS2 genes are deleted, show deficit in learning, memory, synaptic function and neuronal death. The processes beneath these effects are unknown, but the findings that PS1 interacts with antiapoptotic member of Bcl-2 family might indicate a possible mechanism.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  266,\n",
       "  {'Subgraph': ('Cholesterol metabolism', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Recently, also the low-density receptor-related protein (LRP) has been shown to be cleaved by a gamma-secretase-like activity. It is important to note that LRPs receptors are activated by apolipoprotein E, a well-known risk factor for the developing of late onset AD in carriers of the e4 alleles.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  266,\n",
       "  {'CellStructure': ('Centrosome',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Subgraph': ('Low density lipoprotein pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Beside its role as A\\x9f chaperone, ApoE might modulate specific internalization and signaling events via binding to its receptors. Some of them possess shared adaptors with A\\x9fPP; in particular Fe65 and JIP1 bind to LRP8, LRP1, and megalin. Indeed gamma-secretase cleavage regulates the intramembrane proteolysis of LRP8, LRP1, and of SOR-1/LRP11. It is tempting to speculate that LRPs could affect A\\x9fPP processing and signaling (and vice versa) through gamma-secretase and ApoE-mediated stimuli.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  12,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'Notch pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'CNS Drugs. 2006;20(5):351-72.', '16696577'),\n",
       "   'evidence': \"gamma-Secretase comprises a molecular complex of four integral membrane proteins - presenilin, nicastrin, APH-1 and PEN-2 - and its molecular mechanism remains under extensive scrutiny. The ratio of Abeta(42) over Abeta(40) is increased by familial Alzheimer's disease mutations occurring in the presenilin genes or in APP, near the gamma-secretase cleavage site.\",\n",
       "   'rel': 'hasComponents'}),\n",
       " (2,\n",
       "  12,\n",
       "  {'Subgraph': ('Gamma secretase pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    '2010 Apr 13;107(15):6557-8. doi: 10.1073/pnas.1002555107.',\n",
       "    '20385830'),\n",
       "   'evidence': 'The pathogenesis of AD begins with impaired synaptic function, which may result from the accumulation of amyloid-\\x8e (A\\x8e) peptide (5\\x828). For many years, researchers have focused on the insoluble deposits of amyloid fibrils as the leading cause of memory loss and as the culprit of AD. More recent findings, however, suggest soluble A\\x8e oligomers may be the cause of memory loss, especially in the early stages of AD, because A\\x8e oligomers inhibit long-term potentiation in neurons, a well-adopted experimental paradigm for learning and memory (6, 9). A\\x8e is produced from amyloid precursor protein (APP) by serial proteolytic reactions catalyzed by \\x8e-site of APP cleaving enzyme (BACE) and a multiprotein complex \\x8e-secretase, in which presenilin is likely the catalytic component ',\n",
       "   'rel': 'hasComponents'}),\n",
       " (2,\n",
       "  12,\n",
       "  {'Subgraph': ('Gamma secretase pathway',),\n",
       "   'citation': ('PubMed', 'CNS Drugs. 2006;20(5):351-72.', '16696577'),\n",
       "   'evidence': \"gamma-Secretase comprises a molecular complex of four integral membrane proteins - presenilin, nicastrin, APH-1 and PEN-2 - and its molecular mechanism remains under extensive scrutiny. The ratio of Abeta(42) over Abeta(40) is increased by familial Alzheimer's disease mutations occurring in the presenilin genes or in APP, near the gamma-secretase cleavage site.\",\n",
       "   'rel': 'hasComponents'}),\n",
       " (2,\n",
       "  291,\n",
       "  {'Subgraph': ('Cholesterol metabolism', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Recently, also the low-density receptor-related protein (LRP) has been shown to be cleaved by a gamma-secretase-like activity. It is important to note that LRPs receptors are activated by apolipoprotein E, a well-known risk factor for the developing of late onset AD in carriers of the e4 alleles.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  279,\n",
       "  {'Subgraph': ('Notch pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2003 May 30;278(22):20117-23. Epub 2003 Mar 14.',\n",
       "    '12639958'),\n",
       "   'evidence': \"PEN-2 is an integral membrane protein that is a necessary component of the gamma-secretase complex, which is central in the pathogenesis of Alzheimer's disease and is also required for Notch signaling. In the absence of PEN-2, Notch signaling fails to guide normal development in Caenorhabditis elegans, and amyloid beta peptide is not generated from the amyloid precursor protein\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (2,\n",
       "  292,\n",
       "  {'Subgraph': ('Cholesterol metabolism', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Recently, also the low-density receptor-related protein (LRP) has been shown to be cleaved by a gamma-secretase-like activity. It is important to note that LRPs receptors are activated by apolipoprotein E, a well-known risk factor for the developing of late onset AD in carriers of the e4 alleles.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  731,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Biochim Biophys Acta. 2012 Aug;1823(8):1233-41. Epub 2012 May 18.',\n",
       "    '22613765'),\n",
       "   'evidence': '- and -secretase cleave the amyloid precursor protein (APP) to release the amyloidogenic -amyloid peptides (A) and the APP intracellular domain (AICD).',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  92,\n",
       "  {'Subgraph': ('Cholesterol metabolism', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Recently, also the low-density receptor-related protein (LRP) has been shown to be cleaved by a gamma-secretase-like activity. It is important to note that LRPs receptors are activated by apolipoprotein E, a well-known risk factor for the developing of late onset AD in carriers of the e4 alleles.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  92,\n",
       "  {'CellStructure': ('Centrosome',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Subgraph': ('Low density lipoprotein pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Beside its role as A\\x9f chaperone, ApoE might modulate specific internalization and signaling events via binding to its receptors. Some of them possess shared adaptors with A\\x9fPP; in particular Fe65 and JIP1 bind to LRP8, LRP1, and megalin. Indeed gamma-secretase cleavage regulates the intramembrane proteolysis of LRP8, LRP1, and of SOR-1/LRP11. It is tempting to speculate that LRPs could affect A\\x9fPP processing and signaling (and vice versa) through gamma-secretase and ApoE-mediated stimuli.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  289,\n",
       "  {'Subgraph': ('Cholesterol metabolism', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Recently, also the low-density receptor-related protein (LRP) has been shown to be cleaved by a gamma-secretase-like activity. It is important to note that LRPs receptors are activated by apolipoprotein E, a well-known risk factor for the developing of late onset AD in carriers of the e4 alleles.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  290,\n",
       "  {'Subgraph': ('Cholesterol metabolism', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Recently, also the low-density receptor-related protein (LRP) has been shown to be cleaved by a gamma-secretase-like activity. It is important to note that LRPs receptors are activated by apolipoprotein E, a well-known risk factor for the developing of late onset AD in carriers of the e4 alleles.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2, 611, {'rel': 'in_list'}),\n",
       " (2,\n",
       "  2212,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Phosphatidylinositol 3 pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurochem. 2007 Aug;102(3):848-57. Epub 2007 Apr 16',\n",
       "    '17437536'),\n",
       "   'evidence': \"We previously showed that some familial Alzheimer's disease PS mutations cause increased basal and acetylcholine muscarinic receptor-stimulated phospholipase C (PLC) activity which was gamma-secretase dependent.\",\n",
       "   'rel': 'association'}),\n",
       " (2,\n",
       "  293,\n",
       "  {'Subgraph': ('Cholesterol metabolism', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Recently, also the low-density receptor-related protein (LRP) has been shown to be cleaved by a gamma-secretase-like activity. It is important to note that LRPs receptors are activated by apolipoprotein E, a well-known risk factor for the developing of late onset AD in carriers of the e4 alleles.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  294,\n",
       "  {'Subgraph': ('Cholesterol metabolism', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Recently, also the low-density receptor-related protein (LRP) has been shown to be cleaved by a gamma-secretase-like activity. It is important to note that LRPs receptors are activated by apolipoprotein E, a well-known risk factor for the developing of late onset AD in carriers of the e4 alleles.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  294,\n",
       "  {'CellStructure': ('Centrosome',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Subgraph': ('Low density lipoprotein pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Beside its role as A\\x9f chaperone, ApoE might modulate specific internalization and signaling events via binding to its receptors. Some of them possess shared adaptors with A\\x9fPP; in particular Fe65 and JIP1 bind to LRP8, LRP1, and megalin. Indeed gamma-secretase cleavage regulates the intramembrane proteolysis of LRP8, LRP1, and of SOR-1/LRP11. It is tempting to speculate that LRPs could affect A\\x9fPP processing and signaling (and vice versa) through gamma-secretase and ApoE-mediated stimuli.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  7,\n",
       "  {'DiseaseState': ('Mild AD',),\n",
       "   'FDASTATUS': ('Phase 3',),\n",
       "   'Subgraph': ('Inflammatory response pathway',\n",
       "    'Non-amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'J Alzheimers Dis. 2009;17(4):757-60', '19542625'),\n",
       "   'evidence': \"There has been a lot of disappointment surrounding the recent failure of the largest ever study in patients with Alzheimer's disease (AD) with tarenflurbil. A straightforward explanation of this failure is that the gamma-secretase is not the right target for therapy or that, in general, blocking A beta does not produce clinical benefits in AD\",\n",
       "   'rel': 'causesNoChange'}),\n",
       " (2,\n",
       "  7,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Phosphatidylinositol 3 pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurochem. 2007 Aug;102(3):848-57. Epub 2007 Apr 16',\n",
       "    '17437536'),\n",
       "   'evidence': \"We previously showed that some familial Alzheimer's disease PS mutations cause increased basal and acetylcholine muscarinic receptor-stimulated phospholipase C (PLC) activity which was gamma-secretase dependent.\",\n",
       "   'rel': 'association'}),\n",
       " (2,\n",
       "  942,\n",
       "  {'Subgraph': ('Gamma secretase pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    '2010 Apr 13;107(15):6557-8. doi: 10.1073/pnas.1002555107.',\n",
       "    '20385830'),\n",
       "   'evidence': 'The pathogenesis of AD begins with impaired synaptic function, which may result from the accumulation of amyloid-\\x8e (A\\x8e) peptide (5\\x828). For many years, researchers have focused on the insoluble deposits of amyloid fibrils as the leading cause of memory loss and as the culprit of AD. More recent findings, however, suggest soluble A\\x8e oligomers may be the cause of memory loss, especially in the early stages of AD, because A\\x8e oligomers inhibit long-term potentiation in neurons, a well-adopted experimental paradigm for learning and memory (6, 9). A\\x8e is produced from amyloid precursor protein (APP) by serial proteolytic reactions catalyzed by \\x8e-site of APP cleaving enzyme (BACE) and a multiprotein complex \\x8e-secretase, in which presenilin is likely the catalytic component ',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  1534,\n",
       "  {'Subgraph': ('Notch pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2003 May 30;278(22):20117-23. Epub 2003 Mar 14.',\n",
       "    '12639958'),\n",
       "   'evidence': \"PEN-2 is an integral membrane protein that is a necessary component of the gamma-secretase complex, which is central in the pathogenesis of Alzheimer's disease and is also required for Notch signaling. In the absence of PEN-2, Notch signaling fails to guide normal development in Caenorhabditis elegans, and amyloid beta peptide is not generated from the amyloid precursor protein\",\n",
       "   'rel': 'hasMember'}),\n",
       " (2,\n",
       "  1828,\n",
       "  {'DiseaseState': ('Mild AD',),\n",
       "   'FDASTATUS': ('Phase 2',),\n",
       "   'Subgraph': ('Notch pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Prim Care Companion J Clin Psychiatry. 2007; 9(1): 3241',\n",
       "    '17599166'),\n",
       "   'evidence': 'There are 4 classes of potentially disease-modifying treatments that have successfully advanced to later-stage clinical trials: (1) immunotherapies, (2) secretase inhibitors, (3) selective Abeta42-lowering agents (SALAs), and (4) anti-Abeta aggregation agents. Gamma-secretase has many biologically essential substrates. One physiologically important gamma-secretase substrate is the Notch signaling protein',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  2936,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': 'Processing of APP to produce Ab involves cleavage by b-site APP cleaving enzyme-1 (BACE1) and g-secretase that process APP at the N- and C-termini, respectively, of the Ab sequence.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  2936,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': 'In addition, APP can be cleaved by a- and g-secretases and this precludes Ab production since a-secretase cleaves APP within the Ab sequence',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  2936,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': 'Processing of APP to produce Ab involves cleavage by b-site APP cleaving enzyme-1 (BACE1) and g-secretase that process APP at the N- and C-termini, respectively, of the Ab sequence.',\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  2937,\n",
       "  {'Subgraph': ('Gamma secretase pathway',),\n",
       "   'citation': ('PubMed', 'CNS Drugs. 2006;20(5):351-72.', '16696577'),\n",
       "   'evidence': \"gamma-Secretase comprises a molecular complex of four integral membrane proteins - presenilin, nicastrin, APH-1 and PEN-2 - and its molecular mechanism remains under extensive scrutiny. The ratio of Abeta(42) over Abeta(40) is increased by familial Alzheimer's disease mutations occurring in the presenilin genes or in APP, near the gamma-secretase cleavage site.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (2,\n",
       "  11457,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': 'Processing of APP to produce Ab involves cleavage by b-site APP cleaving enzyme-1 (BACE1) and g-secretase that process APP at the N- and C-termini, respectively, of the Ab sequence.',\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3, 611, {'rel': 'in_list'}),\n",
       " (3,\n",
       "  1217,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Akt pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2010 Mar 19;285(12):8515-26. doi: 10.1074/jbc.M109.079079. Epub 2010 Jan 22.',\n",
       "    '20097758'),\n",
       "   'evidence': 'ATXN1 functions as a genetic risk modifier that contributes to AD pathogenesis through a loss-of-function mechanism by regulating beta-secretase cleavage of APP and Abeta levels.',\n",
       "   'rel': 'association'}),\n",
       " (3,\n",
       "  731,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Biochim Biophys Acta. 2012 Aug;1823(8):1233-41. Epub 2012 May 18.',\n",
       "    '22613765'),\n",
       "   'evidence': '- and -secretase cleave the amyloid precursor protein (APP) to release the amyloidogenic -amyloid peptides (A) and the APP intracellular domain (AICD).',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': 'Processing of APP to produce Ab involves cleavage by b-site APP cleaving enzyme-1 (BACE1) and g-secretase that process APP at the N- and C-termini, respectively, of the Ab sequence.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'BMC Neurol. 2012 Jun 15;12(1):38. [Epub ahead of print]',\n",
       "    '22702962'),\n",
       "   'evidence': 'Amyloid plaques consist primarily of amyloid  protein (A), which is produced when APP is cleaved by -secretase and then cleaved again by -secretase as part of the amyloidogenic pathway.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Clin Invest. 2004 Jul;114(1):23-7', '15232608'),\n",
       "   'evidence': 'A\\x9f is generated from APP by concerted proteolysis by \\x9f-secretase, which generates carboxyl-terminal fragments (CTFs) of APP, and then by gamma-secretase.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neuroinflammation. 2011 Nov 2;8:150.',\n",
       "    '22047170'),\n",
       "   'evidence': \"-Amyloid (A) plays a central role in Alzheimer's disease (AD) pathogenesis. Neurons are major sources of A in the brain. However, astrocytes outnumber neurons by at least five-fold. Thus, even a small level of astrocytic A production could make a significant contribution to A burden in AD. Moreover, activated astrocytes may increase A generation. -Site APP cleaving enzyme 1 (BACE1) cleavage of amyloid precursor protein (APP) initiates A production.\",\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    '2010 Apr 13;107(15):6557-8. doi: 10.1073/pnas.1002555107.',\n",
       "    '20385830'),\n",
       "   'evidence': 'The pathogenesis of AD begins with impaired synaptic function, which may result from the accumulation of amyloid-\\x8e (A\\x8e) peptide (5\\x828). For many years, researchers have focused on the insoluble deposits of amyloid fibrils as the leading cause of memory loss and as the culprit of AD. More recent findings, however, suggest soluble A\\x8e oligomers may be the cause of memory loss, especially in the early stages of AD, because A\\x8e oligomers inhibit long-term potentiation in neurons, a well-adopted experimental paradigm for learning and memory (6, 9). A\\x8e is produced from amyloid precursor protein (APP) by serial proteolytic reactions catalyzed by \\x8e-site of APP cleaving enzyme (BACE) and a multiprotein complex \\x8e-secretase, in which presenilin is likely the catalytic component ',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'cat'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'DigestiveSystem': ('Liver',),\n",
       "   'NervousSystem': ('Neurons',),\n",
       "   'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Insulin pathway'),\n",
       "   'UserdefinedCellLine': ('N2a695 cell',),\n",
       "   'citation': ('PubMed',\n",
       "    'Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3907-12. doi: 10.1073/pnas.0807991106. Epub 2009 Feb 23.',\n",
       "    '19237574'),\n",
       "   'evidence': 'We then analyzed the levels of various APP metabolites including the cleavage products of - and -secretases (Fig. 1C). Metformin reduced -cleavage and promoted -cleavage, as evidenced by decreased sAPP and increased APP C-terminal fragment, CTF- (the upper CTF band that resulted from cleavage by BACE1). No change in the levels of full-length PS1 (presenilin 1, the core component of -secretase) or its N-terminal fragment was detected from total cell lysates.',\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': 'Processing of APP to produce Ab involves cleavage by b-site APP cleaving enzyme-1 (BACE1) and g-secretase that process APP at the N- and C-termini, respectively, of the Ab sequence.',\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Cell Adh Migr. 2011 Jul-Aug;5(4):280-92. Epub 2011 Jul 1.',\n",
       "    '21785276'),\n",
       "   'evidence': 'The amyloid-beta (A\\x8e) peptide is the derivative of amyloid precursor protein (APP) generated through sequential proteolytic processing by \\x8e- and \\x8e-secretases. Excessive accumulation of A\\x8e, the main constituent of amyloid plaques, has been implicated in the etiology of Alzheimer disease (AD). ',\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'miRNA pathway',\n",
       "    'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Cell Adh Migr. 2011 Jul-Aug;5(4):280-92. Epub 2011 Jul 1.',\n",
       "    '21785276'),\n",
       "   'evidence': 'Such possibility is further corroborated by the observation that a significant decrease in miR-106b expression was found in sporadic AD patients.On the other hand, two miRNAs (miR-298 and miR-328) was found to regulate BACE mRNA translation, while BACE was responsible for APP processing and A\\x8e production',\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'citation': ('PubMed', 'J Neurochem. 2008 Jul;106(1):392-404', '18397369'),\n",
       "   'evidence': 'The proteolytic cleavage of the amyloid precursor protein (APP) through the alpha-secretase pathway decreases in AD, concurrent with cognitive impairment. This APP cleavage occurs within the beta-amyloid peptide (Abeta) sequence, precluding formation of amyloidogenic peptides and leading to the release of the soluble N-terminal APP fragment (sAPPalpha) which is neurotrophic and procognitive.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  4,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'NervousSystem': ('Central Nervous System',),\n",
       "   'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Biol Psychiatry. 2013 Sep 1;74(5):357-66',\n",
       "    '23312564'),\n",
       "   'evidence': 'Hence, mifepristone induces a novel C-terminal cleavage of APP that prevents it being cleaved by - or -secretase, thereby precluding A generation in the central nervous system; this cleavage and the production of the 17-kDa APP fragment was generated by a calcium-dependent cysteine protease.',\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  5,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Species': ('9606',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': 'BACE1 cleaves -amyloid precursor protein (APP) to generate amyloid  protein (A), a central component of neuritic plaques in AD brains.',\n",
       "   'rel': 'association'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9',\n",
       "    '22249458'),\n",
       "   'evidence': 'oxidative stress-mediated ERK activation contributes to increases in \\x9f-secretase and, thus, an increase of A\\x9f generation in neuronal cells expressing mutant PS2',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Response to oxidative stress pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9',\n",
       "    '22249458'),\n",
       "   'evidence': 'oxidative stress-mediated ERK activation contributes to increases in \\x9f-secretase and, thus, an increase of A\\x9f generation in neuronal cells expressing mutant PS2',\n",
       "   'rel': 'increases'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Cell': ('microglial cell',),\n",
       "   'NervousSystem': ('Neurons',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2012 Mar 9;287(11):8424-33. Epub 2012 Jan 20',\n",
       "    '22267734'),\n",
       "   'evidence': 'Ex vivo studies show that the levels of BACE1 are tightly regulated by the ATases. Specifically, up-regulation of ATase1 and ATase2 increases the levels of BACE1 and the generation of A\\x9f while siRNA-mediated down-regulation of either transferase achieves the opposite effects.',\n",
       "   'rel': 'increases'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2008 Oct 31;283(44):29615-9. Epub 2008 Jul 23.',\n",
       "    '18650430'),\n",
       "   'evidence': 'Interestingly, Fe65 acts as a functional linker between APP and LRP (another type I membrane protein containing two NPXY endocytosis motifs) in modulating endocytic APP trafficking and A\\x9f production. A conformational change introduced by phosphorylation at Thr668 (14 amino acids proximal to the YENPTY motif) interferes with Fe65 binding to APP and facilitates BACE1 and gamma-secretase cleavage of APP.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Endosomal lysosomal pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurosci. 2007 Apr 11;27(15):4052-60.',\n",
       "    '17428983'),\n",
       "   'evidence': 'Abeta is a fragment of amyloid-beta precursor protein (APP) generated in neurons by two proteases, beta- and gamma-secretases. APP and beta-secretase, both present on cell surface, are endocytosed into endosomes to produce Abeta. The molecular mechanism by which neurons trigger the production of Abeta is poorly understood. We describe here evidence that the binding of lipid-carrying apolipoprotein E (ApoE) to receptor apolipoprotein E receptor 2 (ApoER2) triggers the endocytosis of APP, beta-secretase, and ApoER2 in neuroblastoma cells, leading to the production of Abeta. This mechanism, mediated by adaptor protein X11alpha or X11beta (X11alpha/beta), whose PTB (phosphotyrosine-binding) domain binds to APP and a newly recognized motif in the cytosolic domain of ApoER2. Isomorphic form ApoE4 triggers the production of more Abeta than by ApoE2 or ApoE3; thus, it may play a role in the genetic risk of ApoE4 for the sporadic AD.',\n",
       "   'rel': 'increases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'MESHCS',\n",
       "   'subject_translocation_from_value': 'Cell Surface Extensions',\n",
       "   'subject_translocation_to_namespace': 'MESHCS',\n",
       "   'subject_translocation_to_value': 'Endosomes'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Eur J Pharmacol. 2012 Jan 30;675(1-3):15-21. Epub 2011 Dec 7.',\n",
       "    '22166376'),\n",
       "   'evidence': \"The level of \\x9f-site APP-cleaving enzyme 1 (BACE1) has been documented to increase in the brains of patients with Alzheimer's disease, which has resulted in elevation of \\x9f-amyloid (A\\x9f) peptides.\",\n",
       "   'rel': 'increases'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'DigestiveSystem': ('Liver',),\n",
       "   'MeSHDisease': ('Diabetes Mellitus, Type 2',),\n",
       "   'NervousSystem': ('Neurons',),\n",
       "   'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Nerve growth factor pathway'),\n",
       "   'UserdefinedSpecies': ('C elegans',),\n",
       "   'citation': ('PubMed',\n",
       "    'Curr Alzheimer Res. 2009 Jun;6(3):213-23.',\n",
       "    '19519303'),\n",
       "   'evidence': 'CerebraiiR/IGF-1 signaling in APP  metabolism. Binding of insulin and IGF-1  to their receptors leads to autophosphorylation of the -subunit of the IR/IGF-IR and recruitment of IRS-1 /-2. IRS proteins activate mainly two pathways, the PI3 kinase pathway, and the RAS-RAF-MAP kinase cascade. Tau phosphorylation via IR/IGF-1 signaling is influenced by GSK-3and  the tau phosphatase  PP2A. Inter\\xad estingly, mTOR signaling couples the activity ofPP2A and GSK-3in a way that the activities of both enzymes change always in the same direction. suggesting that only a dysregulation of either PP2A or GSK-3induces tau hyperphosphorylation. The PI3K pathway as well as the RAS-RAF-MAPK  cascade regulate different transcription  factors involved in transcriptional  regulation of metabolism and clearance of  \\xad amyloid. APP is cleaved by a.-,  -secretase (BACE-1) and y-secretase (presenilin).  - and subsequent  y-cleavage of APP leads to generation of  -amyloid 1 -4o/ t-42\\x80  IGF-1 signaling promotes a switch lrom TrkA to p75NTR expression leading to increased -secretase activity due to an upregulation of BACE-1 expression. Recent data suggest  that not only BACE-1 is int1uenced  by IRIIGF- IR mediated signals but also a.\\xad secretase activity is stimulated by the PI3K pathway.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'act'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'CellLine': ('SH-SY5Y',),\n",
       "   'DigestiveSystem': ('Liver',),\n",
       "   'FluidAndSecretion': ('Cerebrospinal Fluid',),\n",
       "   'MeSHDisease': ('Hyperinsulinism',),\n",
       "   'NervousSystem': ('Cerebrum',),\n",
       "   'Species': ('10116',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Insulin pathway'),\n",
       "   'UserdefinedCellLine': ('primary cortical neuron',),\n",
       "   'UserdefinedGender': ('Female',),\n",
       "   'UserdefinedSpecies': ('C elegans',),\n",
       "   'citation': ('PubMed',\n",
       "    'Curr Alzheimer Res. 2009 Jun;6(3):213-23.',\n",
       "    '19519303'),\n",
       "   'evidence': \"During aging  changes in the cerebral expression levels  of the  neurotrophin  receptors,  TrkA  (tyrosine  kinase  receptor A)  and  p75l'lTR  (p75 neurotrophin  receptor)  have  been  de\\xad scribed. In  the  human   neuroblastoma cell  line  SHSY5Y as well  as  in  primary  cultured neurons chronic treatment with IGF-1   leads  to a switch  from TrkA  to  p75NTR expression as seen  in aging  brains  [128]. This  switch causes increased 13- secretase activity   indirectly by activation of  neuronal sphin\\xad gomyelinase which  is responsible for hydrolysis of sphin\\xad gomyelin and  the  active liberation of  the  second messenger ceramide (review in (129]). Ceramide is responsible for  the molecular stabilization of  BACE-1, the 13-secretase  which  is rate-limiting for  generation of  A[130]. This  process leads to accumulation of Ap,  connecting IGF-1 R signaling to neu\\xad rotrophin  action  (Fig. l).  \",\n",
       "   'rel': 'rateLimitingStepOf',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Response to oxidative stress pathway',\n",
       "    'Apoptosis pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9',\n",
       "    '22249458'),\n",
       "   'evidence': 'oxidative stress-mediated ERK activation contributes to increases in \\x83\\x92\\x85-secretase and, thus, an increase of A\\x83\\x92\\x85 generation in neuronal cells expressing mutant PS2',\n",
       "   'rel': 'increases'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Raf-MEK-ERK cascade pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Beta secretase pathway',\n",
       "    'Response to oxidative stress pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neuropathol Exp Neurol. 2012 Feb;71(2):130-9',\n",
       "    '22249458'),\n",
       "   'evidence': 'oxidative stress-mediated ERK activation contributes to increases in \\x83\\x92\\x85-secretase and, thus, an increase of A\\x83\\x92\\x85 generation in neuronal cells expressing mutant PS2',\n",
       "   'rel': 'increases'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Pharm Pharmacol. 2011 Aug;63(8):1111-8',\n",
       "    '21718295'),\n",
       "   'evidence': \"Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.\",\n",
       "   'rel': 'negativeCorrelation'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Pharm Pharmacol. 2011 Aug;63(8):1111-8',\n",
       "    '21718295'),\n",
       "   'evidence': \"In this study, we aimed to investigate the possibility of P-gp as a potential therapeutic target for Alzheimer's disease by examining the impact of P-gp up-regulation on the clearance of A, a neuropathological hallmark of Alzheimer's disease.Uptake studies for-radiolabelled A Approximately 10-35% decrease in A intracellular accumulation was observed in cells treated with rifampicin, dexamethasone, caffeine, verapamil, hyperforin, -estradiol and pentylenetetrazole compared with control.\",\n",
       "   'rel': 'decreases'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Pharm Pharmacol. 2011 Aug;63(8):1111-8',\n",
       "    '21718295'),\n",
       "   'evidence': 'Also, fluorescent micrographs showed an inverse relationship between levels of P-gp expression and 5-carboxyfluorescein labelled A (FAM-A42) intracellular accumulation.',\n",
       "   'rel': 'negativeCorrelation'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('T cells pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Beta secretase pathway',\n",
       "    'Immunoglobulin pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'FASEB J. 2009 Aug;23(8):2639-49. doi: 10.1096/fj.08-126383. Epub 2009 Mar 30.',\n",
       "    '19332646'),\n",
       "   'evidence': 'RAGE stimulates functional BACE1 expression through NFAT1 activation, resulting in more Abeta production and deposition in the brain.',\n",
       "   'rel': 'increases'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('ADAM Metallopeptidase pathway',\n",
       "    'Beta secretase pathway',\n",
       "    'Non-amyloidogenic pathway',\n",
       "    'Neuroprotective pathway'),\n",
       "   'citation': ('PubMed', 'PLoS One2011', '21246057'),\n",
       "   'evidence': 'Moreover, NPD1 suppresses Abeta42 peptide shedding by down-regulating beta-secretase-1 (BACE1) while activating the -secretase ADAM10 and up-regulating sAPPalpha, thus shifting the cleavage of betaAPP holoenzyme from an amyloidogenic into the non-amyloidogenic pathway.',\n",
       "   'rel': 'increases'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('ADAM Metallopeptidase pathway',\n",
       "    'Beta secretase pathway',\n",
       "    'Non-amyloidogenic pathway',\n",
       "    'Neuroprotective pathway'),\n",
       "   'citation': ('PubMed', 'Mol Neurobiol2011', '21431475'),\n",
       "   'evidence': 'In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the alphaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway.',\n",
       "   'rel': 'increases'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Proc Natl Acad Sci U S A1999', '10500121'),\n",
       "   'evidence': 'A pathogenic mutation at codons 670/671 in APP (APP Swedish) leads to enhanced cleavage at the beta-secretase scissile bond and increased Abeta formation.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2000', '10956649'),\n",
       "   'evidence': 'The novel transmembrane aspartic protease BACE (for Beta-site APP Cleaving Enzyme) is the beta-secretase that cleaves amyloid precursor protein to initiate beta-amyloid formation.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Histol Histopathol2002', '11813874'),\n",
       "   'evidence': 'A beta is generated by the sequential intracellular cleavage of APP by beta-secretase to generate the N-terminal end of A beta, and intramembranous cleavage by gamma-secretase to generate the C-terminal end.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Acta Biochim Pol2004', '15218540'),\n",
       "   'evidence': \"beta-Secretase, a beta-site amyloid precursor protein (APP) cleaving enzyme (BACE), participates in the secretion of beta-amyloid peptides (Abeta), the major components of the toxic amyloid plaques found in the brains of patients with Alzheimer's disease (AD).\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2004', '15452128'),\n",
       "   'evidence': \"Amyloid-beta (Abeta) the primary component of the senile plaques found in Alzheimer's disease (AD) is generated by the rate-limiting cleavage of amyloid precursor protein (APP) by beta-secretase followed by gamma-secretase cleavage.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Int J Dev Neurosci2004', '15465276'),\n",
       "   'evidence': 'The generation of beta-amyloid peptides requires the enzymatic activity of the beta-site APP-cleaving enzyme 1 (BACE1).',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2005', '15663471'),\n",
       "   'evidence': 'The generation of beta-amyloid peptides by proteolytical processing of the amyloid precursor protein (APP) requires the enzymatic activity of the beta-site APP cleaving enzyme 1 (BACE1).',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'J Biol Chem2005', '15737955'),\n",
       "   'evidence': 'Using an assay that incorporates full-length recombinant APP as a substrate for beta-secretase (BACE), we have identified a series of compounds that inhibit APP processing, but do not affect the cleavage of peptide substrates by BACE1.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2005', '15824102'),\n",
       "   'evidence': 'Sequential processing of amyloid precursor protein (APP) by membrane-bound proteases, BACE1 and gamma-secretase, plays a crucial role in the pathogenesis of Alzheimer disease.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'Proc Natl Acad Sci U S A2005', '15890777'),\n",
       "   'evidence': 'gamma-Secretase is a membrane protein complex that cleaves the beta-amyloid precursor protein (APP) within the transmembrane region, after prior processing by beta-secretase, producing amyloid beta peptides Abeta(40) and Abeta(42).',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2005', '16027115'),\n",
       "   'evidence': 'Release of Abeta from the amyloid precursor protein (APP) requires proteolysis by the beta-site APP-cleaving enzyme (BACE1).',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Neurosci Res2006', '16290302'),\n",
       "   'evidence': 'Abeta is produced from beta-amyloid precursor protein (APP) by beta-secretase and gamma-secretase. beta-Secretase has been identified as beta-site APP cleaving enzyme1 (BACE1).',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'RNA2006', '16888322'),\n",
       "   'evidence': \"The beta-amyloid peptide (Abeta) is a major component of the Alzheimer's disease (AD)-associated senile plaques and is generated by sequential cleavage of the beta-amyloid precursor protein (APP) by beta-secretase and gamma-secretase.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Microbiol2006', '17205046'),\n",
       "   'evidence': \"Amyloid beta-peptide (Abeta), which is a product of the proteolytic effect of beta-secretase (BACE) on an amyloid precursor protein, is closely associated with Alzheimer's disease (AD) pathogenesis.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Am J Pathol2007', '17255335'),\n",
       "   'evidence': 'TNF-alpha directly stimulated beta-site APP-cleaving enzyme (BACE1) expression and enhanced beta-processing of APP in astrocytes.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Peptides2007', '17293005'),\n",
       "   'evidence': 'The peptides not only inhibited the formation of APPbeta (a soluble N-terminal fragment of APP cleaved by beta-secretase), but also significantly reduced Abeta40 production.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Proc Natl Acad Sci U S A2007', '17360493'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulation of the neurotoxic peptide amyloid-beta (Abeta), which is produced by sequential cleavage of amyloid precursor protein (APP) by the aspartyl protease beta-secretase and the presenilin-dependent protease gamma-secretase.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Neurodegener Dis2007', '17536186'),\n",
       "   'evidence': 'Such an approach limits APP processing by beta-secretase, mainly through the endocytic pathway, and overcomes some of the limitations of BACE inhibition.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Proc Natl Acad Sci U S A2007', '17573534'),\n",
       "   'evidence': \"Proteolytic processing of the amyloid precursor protein (APP) by beta-secretase, beta-site APP cleaving enzyme (BACE1), is the initial step in the production of the amyloid beta (Abeta) peptide, which is involved in the pathogenesis of Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Brain Res2007', '17586478'),\n",
       "   'evidence': 'To address this issue, temporal neocortex of 27 AD and 21 non-demented control brains was examined to assess mRNA levels of APP isoforms (total APP, APP containing the Kunitz protease inhibitor domain [APP-KPI] and APP770) and APP metabolic enzymatic partners (the APP cleaving enzymes beta-secretase [BACE] and presenilin-1 [PS-1], and putative clearance molecules, low-density lipoprotein receptor protein [LRP] and apolipoprotein E [apoE]).',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Nat Clin Pract Neurol2007', '17611486'),\n",
       "   'evidence': 'Pathologically, AD is characterized by the deposition in the brain of amyloid-beta peptides derived from proteolysis of amyloid precursor protein (APP) by beta-site APP cleaving enzyme 1 (BACE1) and gamma-secretase.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Curr Alzheimer Res2007', '17908048'),\n",
       "   'evidence': 'Abeta is generated by proteolytic processing of amyloid precursor protein (APP) via beta and gamma-secretases.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2008', '17995932'),\n",
       "   'evidence': 'The PSEN1 AD mutations giving rise to CWP produce unusually high levels of the amyloid beta peptide (Abeta) ending at position 42 or 43, and the main component of CWP is amino-terminally truncated forms of amyloid beta peptide starting after the alternative beta-secretase cleavage site at position 11.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Neurobiol Aging2009', '18079026'),\n",
       "   'evidence': 'Quetiapine also decreased brain Abeta peptides, beta-secretase activity and expression, and the level of C99 (an APP C-terminal fragment following cleavage by beta-secretase) in the transgenic mice.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Bioorg Med Chem Lett2008', '18162398'),\n",
       "   'evidence': \"Proteolytic cleavage of amyloid precursor protein by beta-secretase (BACE-1) and gamma-secretase leads to formation of beta-amyloid (A beta) a key component of amyloid plaques, which are considered the hallmark of Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2008', '18308724'),\n",
       "   'evidence': 'Here we describe that the two enzymatic activities responsible for Abeta production, beta-secretase and gamma-secretase, are inhibited in parallel by cholesterol reduction.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2008', '18410513'),\n",
       "   'evidence': 'There was also an induced expression of the key APP processing enzyme i.e. beta-site APP cleaving enzyme 1 in both high fat/cholesterol-fed C57BL/6 and LDLR-/- mice accompanied by an increased generation of C-terminal fragments of APP.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Biochemistry2008', '18570439'),\n",
       "   'evidence': 'The study provides new cell-based assays for the profiling of small molecule inhibitors of QC and points to conspicuous differences in processing of APP depending on sequence at the beta-secretase cleavage site.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'Scand J Clin Lab Invest2009', '18609117'),\n",
       "   'evidence': 'The Abeta peptide results from cleavage of APP initially by BACE1 to produce the C99 fragment and releases soluble APPbeta (sAPPbeta); C99 is then further cleaved by gamma-secretase leading to the Abeta peptide.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Biochem Biophys Res Commun2008', '18675254'),\n",
       "   'evidence': 'Here, we show that lysines 587 and 595 of APP, which are immediately adjacent to the site of beta-secretase cleavage, are covalently pmodified by SUMO proteins in vivo.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Hypoxia pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2009', '19196431'),\n",
       "   'evidence': 'Specifically, hypoxia significantly increases beta-site APP cleaving enzyme (BACE1) gene transcription through the over-expression of hypoxia inducible factor 1alpha, resulting in increased BACE1 secretase activity and amyloid-beta production.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Scand J Clin Lab Invest2009', '19199126'),\n",
       "   'evidence': 'It is produced from amyloid precursor protein (APP) by proteolytic processing dependent on the beta-site APP-cleaving enzyme 1 (BACE1) and gamma-secretase, and is degraded by a broad range of proteases.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Mol Divers2010', '19330459'),\n",
       "   'evidence': 'Three-dimensional quantitative structure-activity relationship (3D-QSAR) pmodels were developed based on comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA), on a series of 43 hydroxyethylamine derivatives, acting as potent inhibitors of beta-site amyloid precursor protein (APP) cleavage enzyme (BACE-1).',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurosci Res2009', '19405102'),\n",
       "   'evidence': 'beta-Site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is a membrane-bound protease that is essential for the production of beta-amyloid protein (Abeta).',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Hum Mutat2009', '19462468'),\n",
       "   'evidence': 'Expression levels of the amyloid precursor protein (APP) and beta-site amyloid (Abeta) cleaving enzyme 1 (BACE1) have been implicated in Alzheimer disease (AD) progression.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Neurobiol Aging2011', '19464074'),\n",
       "   'evidence': 'The effect of nicotine (2 mg/(kg day)) on Abeta-induced spatial learning and memory impairments was assessed by evaluation of performance in the radial arm water maze (RAWM), in vivo electrophysiological recordings of early-phase long-term potentiation (E-LTP) in urethane-anesthetized rats, and immunoblot analysis to determine changes in the levels of beta-site amyloid precursor protein (APP)-cleaving enzyme (BACE), Abeta and memory-related protei',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Neuromolecular Med2009', '19669607'),\n",
       "   'evidence': \"Beta-site amyloid precursor protein cleaving enzyme (BACE1) is the rate-limiting enzyme for production of beta-amyloid peptides (Abeta), which are proposed to drive the pathological changes found in Alzheimer's disease (AD).\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Exp Gerontol2010', '19698775'),\n",
       "   'evidence': 'Core CSF biomarkers include secreted Abeta and amyloid precursor protein (APP) isoforms, Abeta oligomers and beta-site APP-cleaving enzyme 1 (BACE1).',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'FASEB J2010', '19729516'),\n",
       "   'evidence': 'In the amyloidogenic pathway, a small proportion of APP is cleaved by beta- and gamma-secretases, known as beta-site APP-cleaving enzyme 1 (BACE1) and presenilin, respectively, leading to the secretion of Abeta peptides.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Eur J Pharmacol2009', '19765582'),\n",
       "   'evidence': \"We have recently demonstrated that bis(7)-Cognitin, a promising multifunctional anti-Alzheimer's dimer, can remarkably reduce the generation of amyloid beta peptide (Abeta) by inhibiting beta-secretase (BACE-1) and activating alpha-secretase activity.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurosci Res2010', '19885829'),\n",
       "   'evidence': 'A beta is generated upon the sequential proteolytic cleavage of transmembrane amyloid precursor protein (APP) by two membrane-bound proteases, beta-secretase (BACE1) and the gamma-secretase complex comprising presenilin 1 (PS1), nicastrin, APH-1 and PEN-2.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Prion2009', '19887909'),\n",
       "   'evidence': 'In Alzheimer disease, this feedback loop is disrupted, and the increased level of Abeta oligomers bind to PrP(C) and prevent it from regulating BACE1 activity. PrP(C) interacts with and inhibits the beta-secretase BACE1, the rate-limiting enzyme in the production of Abeta.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2010', '20067575'),\n",
       "   'evidence': \"The beta-site APP cleaving enzyme (BACE1) is responsible for the first step in the production of the beta-amyloid protein of Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2010', '20089133'),\n",
       "   'evidence': \"beta-Site amyloid precursor protein cleaving enzyme 1 (BACE1) initiates amyloid-beta (Abeta) generation that is central to the pathophysiology of Alzheimer's disease (AD). Therefore, lowering Abeta levels by BACE1 manipulations represents a key therapeutic strategy, but it remains unclear whether partial inhibition of BACE1, as expected for AD treatments, can improve memory deficits.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Alzheimers Dis2010', '20157255'),\n",
       "   'evidence': 'Abeta is generated from AbetaPP through an initial cleavage by the beta-secretase, BACE-1, which results in the generation of the soluble AbetaPPbeta fragment (sAbetaPPbeta) and the membrane bound C-terminal fragment beta (CTFbeta or C99). ',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Biochem Biophys Res Commun2010', '20171164'),\n",
       "   'evidence': 'We previously indicated that amyloid beta (Abeta) augments protein levels of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) through oxidative stress.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'Curr Alzheimer Res2010', '20205669'),\n",
       "   'evidence': \"Familial Alzheimer's disease mutations in presenilin 1 do not alter levels of the secreted amyloid-beta protein precursor generated by beta-secretase cleavage.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Biochim Biophys Acta2010', '20303415'),\n",
       "   'evidence': 'Abeta is derived from a type I transmembrane protein, amyloid precursor protein (APP), by the sequential proteolytic events mediated by beta-site APP cleaving enzyme 1 (BACE1) and gamma-secretase.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Mol Brain2010', '20409323'),\n",
       "   'evidence': \"BACKGROUND: A central feature of Alzheimer's disease is the cleavage of the amyloid precursor protein (APP) to form beta-amyloid peptide (Abeta) by the beta-secretase and gamma-secretase enzymes.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Exp Neurol2010', '20451519'),\n",
       "   'evidence': 'Basic understanding of the activities of the amyloid beta peptide (Abeta) and associated proteins such as beta-site APP-cleaving enzyme 1 (BACE1) is necessary to develop effective medical responses to AD.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Exp Neurol2010', '20685197'),\n",
       "   'evidence': \"Cleavage of APP by BACE1 is the first proteolytic step in the production of amyloid-beta (Abeta), which accumulates in senile plaques in Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Neurosci Lett2010', '20727383'),\n",
       "   'evidence': 'Abeta is generated from the beta-amyloid precursor protein (APP) through the proteolysis of beta-site APP cleaving enzyme 1 (BACE1) and gamma-secretase. ',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'BMB Rep2010', '21034535'),\n",
       "   'evidence': \"The Swedish mutation (K595N/M596L) of amyloid precursor protein (APP-swe) has been known to increase abnormal cleavage of cellular APP by Beta-secretase (BACE), which causes tau protein hyperphosphorylation and early-onset Alzheimer's disease (AD).\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Mol Neurobiol2011', '21431475'),\n",
       "   'evidence': 'In human neural cells overexpressing beta-amyloid precursor protein (betaAPP), the lipid mediator suppressed Abeta42 shedding by downregulating beta-secretase (BACE1) while activating the alpha-secretase (ADAM10), thus shifting the betaAPP cleavage from the noxious amyloidogenic pathway into a non-amyloidogenic, neurotrophic pathway. ',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurosci Res2011', '21433051'),\n",
       "   'evidence': 'Amyloid-beta peptide (Abeta) is generated by sequential cleavage of the amyloid precursor protein (APP) by beta-site amyloid precursor protein cleaving enzyme 1 (beta-secretase, or BACE1) and gamma-secretase. ',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Nat Med1998', '9623986'),\n",
       "   'evidence': 'To release the amyloidogenic peptide A beta from the Alzheimer amyloid precursor protein (APP), two secretases act sequentially: first, beta-secretase cleaves close to the membrane within the ectodomain and then gamma-secretase cuts within the transmembrane domain.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Prog Neurobiol1998', '9775403'),\n",
       "   'evidence': 'Proteolytic processing of APP by beta-secretase, on the other hand, exposes the N-terminus of beta-amyloid, which is liberated after gamma-secretase cleavage at the variable amyloid C-terminus.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Mol Neurosci1998', '10096041'),\n",
       "   'evidence': 'Pulse-chase experiments revealed beta-secretase cleavage from immature full-length amyloid precursor protein harboring the Swedish mutation.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Nature1999', '10591213'),\n",
       "   'evidence': \"Solubilized Asp2 protein cleaves a synthetic APP peptide substrate at the beta-secretase site, and the rate of cleavage is increased tenfold by a mutation associated with early-onset Alzheimer's disease in Sweden.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Mol Cell Neurosci1999', '10656250'),\n",
       "   'evidence': 'Transient expression of Asp 2 in cells expressing APP causes an increase in the secretion of the N-terminal fragment of APP and an increase in the cell-associated C-terminal beta-secretase APP fragment.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Proc Natl Acad Sci U S A2000', '10677483'),\n",
       "   'evidence': 'Recombinant memapsin 2 specifically hydrolyzed peptides derived from the beta-secretase site of both the wild-type and Swedish mutant beta-amyloid precursor protein (APP) with over 60-fold increase of catalytic efficiency for the latter. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Neurobiol Dis2000', '11114266'),\n",
       "   'evidence': 'IFNgamma in combination with TNFalpha or IL-1beta seems to trigger Abeta production by supporting beta-secretase cleavage of the immature APP molecule.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Traffic2001', '11737828'),\n",
       "   'evidence': 'Amyloid precursor protein/P-selectin, which is sorted from early to late endosomes, undergoes significantly less alpha-secretase cleavage, and more beta-secretase cleavage, than amyloid precursor protein/P-selectin768A, a mutant that recycles more efficiently to the cell surface.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Am J Pathol2002', '11839594'),\n",
       "   'evidence': 'Homeostatic APPsbetaswe levels with aging suggest that progressive amyloid deposition in brain results not from increased beta-secretase cleavage of APP but from impaired Abeta/amyloid clearance mechanisms.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2002', '11953452'),\n",
       "   'evidence': 'ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2002', '11953458'),\n",
       "   'evidence': \"beta-Site APP-cleaving enzyme (BACE) initiates the processing of the amyloid precursor protein (APP) leading to the generation of beta-amyloid, the main component of Alzheimer's disease senile plaques.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Ann Neurol2002', '12112088'),\n",
       "   'evidence': \"Beta-secretase cleavage represents the first step in the generation of Abeta polypeptides and initiates the amyloid cascade that leads to neurodegeneration in Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2002', '12423249'),\n",
       "   'evidence': 'We show that, in Sf9 cells, BACE performs the expected beta-secretase cleavage of APP, generating C99.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Neurobiol Aging2002', '12470797'),\n",
       "   'evidence': 'Our recent knockout studies show that BACE1 is critical for Abeta generation, but the knockout mice show an otherwise normal phenotype, raising the possibility that therapeutic BACE1 inhibition could be accomplished without major mechanism based toxicity.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2003', '12473667'),\n",
       "   'evidence': 'BACE1 is a membrane-bound aspartic protease that cleaves the amyloid precursor protein (APP) at the beta-secretase site, a critical step in the Alzheimer disease pathogenesis.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Cell Biol2003', '12515826'),\n",
       "   'evidence': 'APP is cleaved either by beta-secretase or by alpha-secretase to initiate amyloidogenic (release of A beta) or nonamyloidogenic processing of APP, respectively.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2003', '12603825'),\n",
       "   'evidence': 'Employing a superior BACE1 cleavage sequence to probe cellular APP processing.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Mol Neurosci2003', '14501002'),\n",
       "   'evidence': 'An integral membrane aspartyl protease, BACE, is responsible for beta-secretase processing of the beta-amyloid precursor protein (APP) to the large secreted sAPPbeta and membrane-bound CTFbeta of 99 residues.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Cell Biol2003', '14530380'),\n",
       "   'evidence': 'Here we report evidence that heparan sulfate (HS) interacts with beta-site APP-cleaving enzyme (BACE) 1 and regulates its cleavage of APP.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Cell Biol2003', '14557249'),\n",
       "   'evidence': 'Together, these results suggest that T668 phosphorylation may facilitate the BACE1 cleavage of APP to increase Abeta generation.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2004', '14600149'),\n",
       "   'evidence': 'Our results indicate that BACE1 siRNA specifically impacts on beta-cleavage of APP and may be a potential therapeutic approach for treating AD.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Anal Biochem2003', '14622952'),\n",
       "   'evidence': \"The cerebral deposition of amyloid beta-peptide (Abeta) is a major factor in the etiology of Alzheimer's disease. beta-Secretase (BACE) initiates the generation of Abeta by cleaving the amyloid precursor protein at the beta-site and is therefore a prime target for therapeutic intervention.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'Mol Cell Biol2004', '14701757'),\n",
       "   'evidence': 'BACE1, the major beta-secretase involved in cleaving APP, has been identified as a type 1 membrane-associated aspartyl protease.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Neuron2004', '14715132'),\n",
       "   'evidence': \"beta-site APP cleaving enzyme 1 (BACE1) is the beta-secretase enzyme required for generating pathogenic beta-amyloid (Abeta) peptides in Alzheimer's disease (AD).\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Glycoconj J2004', '14973371'),\n",
       "   'evidence': \"Alzheimer's beta-secretase (BACE1) is a membrane-bound protease that cleaves the amyloid precursor protein (APP) in the trans-Golgi network, an initial step in the pathogenesis of Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neural Transm2004', '15057522'),\n",
       "   'evidence': 'The activity of BACE-1 as measured by the formation of the cleavage product of amyloid beta precursor protein, transiently increased up to 48 h after injury, but returned to basal level 7 days post injury.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Mol Cell Neurosci2004', '15080893'),\n",
       "   'evidence': \"BACE is an aspartyl protease that cleaves the amyloid precursor protein (APP) at the beta-secretase cleavage site and is involved in Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurosci Res2004', '15211591'),\n",
       "   'evidence': 'The beta-site APP-cleaving enzyme (BACE1) has been identified as the key enzyme leading to beta-amyloid formation, and cholinergic mechanisms have been shown to control APP processing.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Mol Neurosci2004', '15314262'),\n",
       "   'evidence': 'Because alpha-secretase and BACE-1 cleave APP within the secretory pathway, it is likely that the two enzymes compete for the APP substrate.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Glycoconj J2004', '15467394'),\n",
       "   'evidence': \"Alzheimer's beta-secretase (BACE1) cleaves amyloid precursor protein to produce amyloid beta-peptide, which is a crucial initiation process of the pathogenesis of Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Proteome Res2004', '15473697'),\n",
       "   'evidence': 'Mapping to the Down syndrome critical region (chromosome 21) and identified as a homologue of BACE1, BACE2 also cleaves amyloid precursor protein at the beta-site.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2004', '15584903'),\n",
       "   'evidence': 'Preventing Abeta42 production with an M596I mutation (beta-), which blocks beta-secretase cleavage of APP, or by treatment with a gamma-secretase inhibitor increased the resistance of APP(FAD)-expressing cells to apoptosis.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Cell Biol2005', '15642747'),\n",
       "   'evidence': 'Although pmodest overexpression enhanced amyloid deposition, high BACE overexpression inhibited amyloid formation despite increased beta-cleavage of APP. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Cell Biol2005', '15767460'),\n",
       "   'evidence': 'Here, we established a novel approach to regulate production of Abeta based on intracellular expression of single chain antibodies (intrabodies) raised to an epitope adjacent to the beta-secretase cleavage site of human APP.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'FASEB J2005', '15857888'),\n",
       "   'evidence': 'BACE1 increased APP cleavage at the beta-site and Abeta production whereas BACE2 did not.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Structure2005', '16216580'),\n",
       "   'evidence': \"The aspartic protease beta-secretase (BACE) cleaves the amyloid precursor protein into a 42 residue beta-peptide, which is the principal biochemical marker of Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurosci2005', '16306400'),\n",
       "   'evidence': \"Beta-secretase [beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1)] is the key rate-limiting enzyme for the production of the beta-amyloid (Abeta) peptide involved in the pathogenesis of Alzheimer's disease (AD).\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'EMBO J2006', '16407971'),\n",
       "   'evidence': 'This was associated with inefficient plasminogen binding and plasmin activation, the displacement of beta-secretase (BACE) from DRMs to APP-containing membrane fractions, increased beta-cleavage of APP and high levels of Abeta peptides.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Biochemistry2006', '16716081'),\n",
       "   'evidence': 'Heparin can promote beta-secretase cleavage of APP in neuroblastoma cells.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Bull Mem Acad R Med Belg2005', '16768248'),\n",
       "   'evidence': 'In AD, the specific inhibition of beta- or beta-secretase activities would decrease the production of Abeta from its precursor, in such a way that its relative concentration could be low enough to avoid the formation of aggregates.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Mol Biol2006', '16979658'),\n",
       "   'evidence': 'BACE1 is a membrane-bound aspartyl protease that specifically cleaves amyloid precursor protein (APP) at the beta-secretase site.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Proc Natl Acad Sci U S A2006', '17098871'),\n",
       "   'evidence': 'Using high-throughput siRNA screening technology, we assessed 15,200 genes for their role in Abeta42 secretion and identified leucine-rich repeat transmembrane 3 (LRRTM3) as a neuronal gene that promotes APP processing by BACE1. siRNAs targeting LRRTM3 inhibit the secretion of Abeta40, Abeta42, and sAPPbeta, the N-terminal APP fragment produced by BACE1 cleavage, from cultured cells and primary neurons by up to 60%, whereas overexpression increases Abeta secretion.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Hypoxia pathway'),\n",
       "   'citation': ('PubMed', 'Proc Natl Acad Sci U S A2006', '17121991'),\n",
       "   'evidence': 'Hypoxia up-regulated beta-secretase cleavage of APP and amyloid-beta protein (Abeta) production by increasing BACE1 gene transcription and expression both in vitro and in vivo.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2007', '17156133'),\n",
       "   'evidence': \"Consequently, inhibition of BACE-1, a rate-limiting enzyme in the production of Abeta, is an attractive therapeutic approach for the treatment of Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Neurosci Lett2007', '17223266'),\n",
       "   'evidence': 'In addition, we show that some NF-kappaB inhibitors decrease sAPPbeta and APP-CTFbeta suggesting that they reduce the beta-secretase cleavage of APP.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurosci2007', '17409228'),\n",
       "   'evidence': \"Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) (beta-secretase) initiates generation of beta-amyloid (Abeta), which plays an early role in Alzheimer's disease (AD).\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Comput Biol Chem2007', '17500040'),\n",
       "   'evidence': \"Beta-secretase is a potential target for inhibitory drugs against Alzheimer's disease as it cleaves amyloid precursor protein (APP) to form insoluble amyloid plaques and vascular deposits in the brain.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Anal Bioanal Chem2007', '17541560'),\n",
       "   'evidence': \"Consequently, inhibition of BACE-1, a rate-limiting enzyme in the production of Abeta, is an attractive therapeutic approach to the treatment of Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Neuron2007', '17553422'),\n",
       "   'evidence': \"Beta-site APP-cleaving enzyme (BACE) is required for production of the Alzheimer's disease (AD)-associated Abeta protein.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2007', '17616527'),\n",
       "   'evidence': 'The aspartyl protease beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) initiates processing of amyloid precursor protein (APP) into amyloid beta (Abeta) peptide, the major component of Alzheimer disease (AD) plaques.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Bioorg Med Chem Lett2008', '18068983'),\n",
       "   'evidence': \"The proteolytic enzyme beta-secretase (BACE-1) produces amyloid beta (Abeta) peptide, the primary constituent of neurofibrillary plaques, implicated in Alzheimer's disease, by cleavage of the amyloid precursor protein.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'J Biol Chem2008', '18184658'),\n",
       "   'evidence': 'After inhibitor treatment, the improved memory function was accompanied by reduced amyloid plaque load, decreased Abeta40 and Abeta42, and reduced C-terminal beta-secretase fragment derived from APP by beta-secretase.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2008', '18263584'),\n",
       "   'evidence': 'Beta-amyloid (Abeta) peptides that accumulate in Alzheimer disease are generated from the beta-amyloid precursor protein (betaAPP) by cleavages by beta-secretase BACE1 and by presenilin-dependent gamma-secretase activities.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Biochim Biophys Acta2008', '18295609'),\n",
       "   'evidence': 'Consequently, inhibition of BACE-1, a rate-limiting enzyme in the production of Abeta, is an attractive therapeutic approach for the treatment of AD.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Expert Opin Ther Targets2008', '18479216'),\n",
       "   'evidence': 'In our opinion, albeit based on limited available data, a future potential therapeutic strategy is to mimic the mechanism by which the normal cellular form of the prion protein inhibits the beta-secretase beta-site amyloid precursor protein cleaving enzyme-1 (BACE1), and hence the production of Abeta.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'CNS Neurol Disord Drug Targets2008', '18673212'),\n",
       "   'evidence': 'BACE-1 cleavage is limiting for the production of Abeta, making it a particularly good drug target for the generation of inhibitors that lower Abeta.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Biol Chem2008', '18979625'),\n",
       "   'evidence': 'One group described the poor kinetics of BACE 1 for cleaving the wild-type (WT) beta-secretase site of APP found in most AD patients.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'J Biol Chem2009', '19074428'),\n",
       "   'evidence': 'These results indicate that post-translational S-palmitoylation of BACE1 is not required for APP processing, and that BACE1 can efficiently cleave APP in both raft and non-raft microdomains.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'FASEB J2009', '19332646'),\n",
       "   'evidence': 'Because beta-site APP-cleaving enzyme 1 (BACE1), an essential protease for Abeta production, is up-regulated in cells overexpressing RAGE and in RAGE-injected brains of Tg2576 mice, the molecular mechanisms underlying RAGE, BACE1 expression, and Abeta production were examined.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2009', '19366692'),\n",
       "   'evidence': 'However, unlike BRI2, the binding of BRI3 to the beta-secretase cleaved APP C-terminal fragment is negligible and BRI3 does not cause the massive accumulation of this APP fragment, suggesting that, unlike BRI2, BRI3 is a poor gamma-cleavage inhibitor.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Curr Med Chem2009', '19442147'),\n",
       "   'evidence': 'BACE 1 (beta-site APP-cleaving enzyme 1 or beta-secretase), the key enzyme required for generating Abeta from the beta-amyloid precursor protein (APP), is regarded as an ideal target for AD therapeutic drug design.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurosci2009', '19828790'),\n",
       "   'evidence': 'The beta-secretase, beta-site amyloid precursor protein cleaving enzyme (BACE1; also called Asp2, memapsin 2), is the enzyme responsible for initiating Abeta generation.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Eur J Neurosci2009', '20092570'),\n",
       "   'evidence': 'BACE1 initiates the amyloidogenic processing of APP; therefore, early or active amyloidogenic loci might exhibit site-specific BACE1 and Abeta elevation.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2010', '20097758'),\n",
       "   'evidence': 'Taken together, ATXN1 functions as a genetic risk pmodifier that contributes to AD pathogenesis through a loss-of-function mechanism by regulating beta-secretase cleavage of APP and Abeta levels.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Nat Rev Neurol2010', '20139999'),\n",
       "   'evidence': 'Three proteases that are involved in the processing of amyloid precursor protein-alpha-secretase, beta-secretase and gamma-secretase-are of particular interest as they are central to the generation and pmodulation of amyloid-beta peptide and can be targeted by small compounds in vitro and in vivo.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Sci Transl Med2010', '20371462'),\n",
       "   'evidence': 'Although pmoderate decreases of either gamma-secretase or BACE1 are not associated with mechanism-based toxicities, they provide only pmodest benefits in reducing Abeta in the brains of APPswe/PS1DeltaE9 mice.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'Neuropathology2010', '20374499'),\n",
       "   'evidence': 'Reticulons are a group of membrane-bound proteins involved in diverse cellular functions, and are suggested to act as inhibitors of beta-secretase enzyme 1 (BACE1) activity that cleaves amyloid precursor protein.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'J Neurosci2010', '20592218'),\n",
       "   'evidence': 'Here we tested the possibility of targeting the cellular environment of beta-secretase cleavage instead of the beta-secretase enzyme itself. beta-Secretase has an acidic pH optimum and cleaves the amyloid precursor protein in the acidic endosomes.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'Curr Alzheimer Res2010', '20704561'),\n",
       "   'evidence': \"ABCA2 expression promoted b-secretase (BACE1) cleavage of APP not at the common Asp1 amino acid site (beta-site) of Abeta in APP but at the Glu11 site (beta'-site) to increase C89 carboxyl-terminal fragment levels (beta'-CTF/C89).\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurosci2010', '20720123'),\n",
       "   'evidence': \"We discovered a nonpeptidic compound, TAK-070, that inhibited BACE1, a rate-limiting protease for the generation of Abeta peptides that are considered causative for Alzheimer's disease (AD), in a noncompetitive manner.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'Eur J Neurosci2010', '20726888'),\n",
       "   'evidence': 'Western blot analyses detected increased levels of BACE1 protein and beta-site-cleavage amyloid precursor protein C-terminal fragments in plaque-bearing human and monkey cortex relative to controls. ',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'PLoS One2010', '20886088'),\n",
       "   'evidence': \"beta-Site APP-cleaving enzyme 1 (BACE1) initiates amyloid-beta (Abeta) generation and thus represents a prime therapeutic target in treating Alzheimer's disease (AD).\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Mol Brain2010', '21059265'),\n",
       "   'evidence': 'Importantly, recent evidence reveals that expression and activity levels of the beta-site APP cleaving enzyme 1 (BACE1), which initiates amyloid-beta (Abeta) production, are elevated in AD brains.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'J Biol Chem2011', '21245145'),\n",
       "   'evidence': 'BACE1 (beta-site beta-amyloid precursor protein (APP)-cleaving enzyme 1) mediates the first proteolytic cleavage of APP, leading to amyloid beta-peptide (Abeta) production.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'J Biol Chem1995', '7876155'),\n",
       "   'evidence': 'Increased beta-secretase cleavage of APP after introduction of the Swedish double mutation causes apical missorting of about 20% of beta-secretase-cleaved APP.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem1996', '8621560'),\n",
       "   'evidence': 'Taken together, the data suggest that the processing pathway for betaPP is similar for both betaPP-wt and betaPP-sw cells and that increased Abeta production by betaPP-sw cells arises from enhanced cleavage of mutant betaPP by beta-secretase, the as-yet unidentified enzyme(s) that cleaves at the NH2 terminus of Abeta.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'Neurochem Int1997', '9152995'),\n",
       "   'evidence': \"Heparin promotes beta-secretase cleavage of the Alzheimer's amyloid precursor protein.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Biol Chem2010', '20731541'),\n",
       "   'evidence': 'Sequential proteolytic cleavage of APP by beta-secretase and gamma-secretase liberates Abeta from APP.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Nat Med1997', '9055862'),\n",
       "   'evidence': \"Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and beta-amyloid precursor protein.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'citation': ('PubMed', 'J Biol Chem2000', '10956649'),\n",
       "   'evidence': \"The novel transmembrane aspartic protease BACE (for Beta-site APP Cleaving Enzyme) is the beta-secretase that cleaves amyloid precursor protein to initiate beta-amyloid formation. As such, BACE is a prime therapeutic target for the treatment of Alzheimer's disease. \",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Cell Sci2004', '15466887'),\n",
       "   'evidence': \"beta-Secretase (BACE) carries out the first of two proteolysis steps to generate the amyloid-beta peptides that accumulate in the senile plaques in Alzheimer's disease (AD). \",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Proc Natl Acad Sci U S A2006', '17098871'),\n",
       "   'evidence': 'LRRTM3 promotes processing of amyloid-precursor protein by BACE1',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurochem2004', '15189355'),\n",
       "   'evidence': \"The complex mediates the intramembraneous proteolysis of beta-secretase cleaved beta-amyloid precursor protein (APP) leading to the secretion of the Alzheimer's disease-associated amyloid beta-peptide (Abeta).\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2002', '11724784'),\n",
       "   'evidence': \"The familial Alzheimer's disease gene product amyloid beta precursor protein (APP) is sequentially processed by beta- and gamma-secretases to generate the Abeta peptide.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  6,\n",
       "  {'Duration_of_Chemical_Exposure': ('Chronic',),\n",
       "   'Species': ('10090',),\n",
       "   'citation': ('PubMed',\n",
       "    'Free Radic Biol Med. 2009 May 1;46(9):1241-9. doi: 10.1016/j.freeradbiomed.2009.02.006. Epub 2009 Feb 23.',\n",
       "    '19245828'),\n",
       "   'evidence': 'Down regulation of DNMT results in hypomethylation of BACE1 and APP which are involved in Abeta production and causes upregulation of their protein expression; in turn SP1 transcription factor increases which finally results in Abeta production.',\n",
       "   'rel': 'increases'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Dev Neurosci. 2004 Nov;22(7):467-74.',\n",
       "    '15465276'),\n",
       "   'evidence': 'BACE1 is primarily expressed by neurons and increased BACE1 protein concentrations and enzymatic activities have been reported in the brains of AD patients. However, there is accumulating evidence that, in addition to neurons, reactive astrocytes are capable of expressing BACE1 and, therefore, may contribute to beta-amyloid plaque formation. This suggests that conditions accompanied by chronic astrocyte activation may contribute to developing AD.',\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'citation': ('PubMed', 'J Neurochem. 2008 Jul;106(1):392-404', '18397369'),\n",
       "   'evidence': 'The proteolytic cleavage of the amyloid precursor protein (APP) through the alpha-secretase pathway decreases in AD, concurrent with cognitive impairment. This APP cleavage occurs within the beta-amyloid peptide (Abeta) sequence, precluding formation of amyloidogenic peptides and leading to the release of the soluble N-terminal APP fragment (sAPPalpha) which is neurotrophic and procognitive.',\n",
       "   'rel': 'positiveCorrelation',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Nuclear factor Kappa beta pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': \"Increased NF-B signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.\",\n",
       "   'rel': 'association'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Species': ('9606',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Nuclear factor Kappa beta pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': \"Elevated levels of -site APP cleaving enzyme 1 (BACE1) were found in the brain of some sporadic Alzheimer's disease (AD) patients; however, the underlying mechanism is unknown.\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'MeSHDisease': ('Plaque, Amyloid',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Species': ('9606',),\n",
       "   'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': 'In this report we found that both BACE1 and NF-B p65 levels were significantly increased in the brains of AD patients.',\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed', 'J Med Chem. 2012 Nov 8;55(21):9224-39', '22984865'),\n",
       "   'evidence': \"-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2004', '15452128'),\n",
       "   'evidence': 'Our studies demonstrate, for the first time, that pmodulation of BACE1 activity may play a significant role in AD pathogenesis in vivo.',\n",
       "   'rel': 'association',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed', 'Neurosci Res2006', '16290302'),\n",
       "   'evidence': 'Taken together, these findings suggest that those neurons that survive in AD brains might generate more BACE1 than normal neurons in control brains, indicating that increased BACE1 activity could be one of the causes of AD. ',\n",
       "   'rel': 'increases'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Mol Cell Neurosci2004', '15080893'),\n",
       "   'evidence': \"BACE is an aspartyl protease that cleaves the amyloid precursor protein (APP) at the beta-secretase cleavage site and is involved in Alzheimer's disease.\",\n",
       "   'rel': 'association'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Glycoconj J2004', '15467394'),\n",
       "   'evidence': \"Alzheimer's beta-secretase (BACE1) cleaves amyloid precursor protein to produce amyloid beta-peptide, which is a crucial initiation process of the pathogenesis of Alzheimer's disease.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed', 'FASEB J2008', '18413858'),\n",
       "   'evidence': \"BACE1 is a promising therapeutic and preventive target for Alzheimer's disease because it is essential for amyloid deposition.\",\n",
       "   'rel': 'association'}),\n",
       " (3,\n",
       "  2936,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': 'Processing of APP to produce Ab involves cleavage by b-site APP cleaving enzyme-1 (BACE1) and g-secretase that process APP at the N- and C-termini, respectively, of the Ab sequence.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  2936,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': 'Processing of APP to produce Ab involves cleavage by b-site APP cleaving enzyme-1 (BACE1) and g-secretase that process APP at the N- and C-termini, respectively, of the Ab sequence.',\n",
       "   'rel': 'directlyIncreases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  2937,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Alzheimers Dis. 2010;22(3):741-63', '20847424'),\n",
       "   'evidence': 'Physiological levels of A\\x83 also have trophic and neuroprotective actions in trophic deprived conditions [95]. Many A\\x83 has a physiological role in normal synapse function. In organotypic hippocampal slices, BACE activity is increased by synaptic activity and the resulting A\\x83 peptides depress excitatory transmission through a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) and N-methyl-D-aspartic acid (NMDA) receptors, suggesting a role for A\\x83 in homeostatic plasticity [29]. A\\x83 may have an important physiological role in synapse elimination during brain development',\n",
       "   'rel': 'increases'}),\n",
       " (3,\n",
       "  155,\n",
       "  {'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed', 'J Biol Chem2005', '16027115'),\n",
       "   'evidence': 'These results demonstrate that high levels of BACE1 activity are sufficient to elicit neurodegeneration and neurological decline in vivo.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'pep'}),\n",
       " (3,\n",
       "  942,\n",
       "  {'Subgraph': ('Gamma secretase pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    '2010 Apr 13;107(15):6557-8. doi: 10.1073/pnas.1002555107.',\n",
       "    '20385830'),\n",
       "   'evidence': 'The pathogenesis of AD begins with impaired synaptic function, which may result from the accumulation of amyloid-\\x8e (A\\x8e) peptide (5\\x828). For many years, researchers have focused on the insoluble deposits of amyloid fibrils as the leading cause of memory loss and as the culprit of AD. More recent findings, however, suggest soluble A\\x8e oligomers may be the cause of memory loss, especially in the early stages of AD, because A\\x8e oligomers inhibit long-term potentiation in neurons, a well-adopted experimental paradigm for learning and memory (6, 9). A\\x8e is produced from amyloid precursor protein (APP) by serial proteolytic reactions catalyzed by \\x8e-site of APP cleaving enzyme (BACE) and a multiprotein complex \\x8e-secretase, in which presenilin is likely the catalytic component ',\n",
       "   'rel': 'increases'}),\n",
       " (4, 6, {'rel': 'product'}),\n",
       " (4,\n",
       "  7,\n",
       "  {'Subgraph': ('ADAM Metallopeptidase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2013 May 10;288(19):13748-61. doi: 10.1074/jbc.M112.381392. Epub 2013 Apr 1.',\n",
       "    '23546882'),\n",
       "   'evidence': \"Amyloid \\x83\\x82-peptide (A\\x83\\x82) accumulating in the brain of Alzheimer disease (AD) patients is believed to be the main pathophysiologcal cause of the disease. Proteolytic processing of the amyloid precursor protein by \\x83\\x82-secretase ADAM10 (a disintegrin and metalloprotease 10) protects the brain from the production of the A\\x83\\x82. Meanwhile, dysregulation or aberrant expression of microRNAs (miRNAs) has been widely documented in AD patients. In this study, we demonstrated that overexpression of miR-144, which was previously reported to be increased in elderly primate brains and AD patients, significantly decreased activity of the luciferase reporter containing the ADAM10 3'-untranslated region (3'-UTR) and suppressed the ADAM10 protein level, whereas the miR-144 inhibitor led to an increase of the luciferase activity. The negative regulation caused by miR-144 was strictly dependent on the binding of the miRNA to its recognition element in the ADAM10 3'-UTR. Moreover, we also showed that activator protein-1 regulates the transcription of miR-144 and the up-regulation of miR-144 at least partially induces the suppression of the ADAM10 protein in the presence of A\\x83\\x82. In addition, we found that miR-451, a miRNA processed from a single gene locus with miR-144, is also involved in the regulation of ADAM10 expression. Taken together, our data therefore demonstrate miR-144/451 is a negative regulator of the ADAM10 protein and suggest a mechanistic role for miR-144/451 in AD pathogenesis.\",\n",
       "   'rel': 'increases'}),\n",
       " (5, 611, {'rel': 'in_list'}),\n",
       " (5,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Species': ('9606',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': 'BACE1 cleaves -amyloid precursor protein (APP) to generate amyloid  protein (A), a central component of neuritic plaques in AD brains.',\n",
       "   'rel': 'association'}),\n",
       " (5,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Brain Res Mol Brain Res2001', '11744168'),\n",
       "   'evidence': \"Expression of familial Alzheimer's disease (FAD) mutants of APP in primary neurons causes both intracellular accumulation of the C-terminal beta-secretase cleavage product of APP and increased secretion of Abeta, and eventually results in apoptotic death of the cells.\",\n",
       "   'rel': 'increases'}),\n",
       " (5,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed', 'BMB Rep. 2010 Oct;43(10):656-63.', '21034527'),\n",
       "   'evidence': 'Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3\\x83, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes',\n",
       "   'object_activity': 'act',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'tscript'}),\n",
       " (5, 4, {'rel': 'reactant'}),\n",
       " (5,\n",
       "  5,\n",
       "  {'citation': ('PubMed', 'BMB Rep. 2010 Oct;43(10):656-63.', '21034527'),\n",
       "   'evidence': 'Although the role of AICD as a gene transcription inducer is still controversial, several targets of AICD- or APP-mediated transcriptional activation are reportedly regulated by APP nuclear signaling, including APP itself, BACE, Tip60, GSK-3\\x83, p53, Mn-SOD, KAI1, Neprilysin, transgelin, a2actin, S100a9, and other genes',\n",
       "   'object_activity': 'act',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'tscript'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Non-amyloidogenic pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': \"Calsyntenin-1 is a ligand for kinesin-1 light chains and APP is transported through axons on kinesin-1 molecular motors. Defects in axonal transport are an early pathological feature in Alzheimer's disease and defective APP transport is known to increase A\\x9f production. We show that calsyntenin-1 and APP are co-transported through axons and that siRNA-induced loss of calsyntenin-1 markedly disrupts axonal transport of APP. Thus, perturbation to axonal transport of APP on calsyntenin-1 containing carriers induces alterations to APP processing that increase production of A\\x9f. Together, our findings suggest that disruption of calsyntenin-1-associated axonal transport of APP is a pathogenic mechanism in Alzheimer's disease.\",\n",
       "   'rel': 'decreases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'UNDEFINED',\n",
       "   'subject_translocation_from_value': 'UNDEFINED',\n",
       "   'subject_translocation_to_namespace': 'UNDEFINED',\n",
       "   'subject_translocation_to_value': 'UNDEFINED'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'CellStructure': ('Centrosome',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Subgraph': ('Amyloidogenic pathway', 'Reelin pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Upon binding, LRP8 transduces reelin signaling during neuronal development, and recent evidence has indicated that it interacts with the NR2A and NR2B subunits of NMDA receptor, being involved in neuronal functions such as maturation of NMDA receptor composition in the hippocampus, and the regulation of long-term potentiation. Subsequently, a novel interaction between reelin and A\\x9fPP was discovered, leading to increase in the cell surface levels of A\\x9fPP and affecting A\\x9fPP processing and A\\x9f production. It was shown that reelin signaling in excitatory synapses can restore normal synaptic plasticity, which is impaired by oligomeric A\\x9f peptides at concentrations within the range detectable in the brains of AD patients. At high concentrations of A\\x9f peptides, reelin can no longer overcome the A\\x9f-induced functional suppression, and this condition coincides with a complete blockade of the reelin-dependent phosphorylation of NR2 subunits in NMDA receptors. This reversal requires the LRP receptor-dependent activation of tyrosine kinases of the Src family.',\n",
       "   'rel': 'increases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'MESHCL',\n",
       "   'subject_translocation_from_value': 'Intracellular Space',\n",
       "   'subject_translocation_to_namespace': 'MESHCL',\n",
       "   'subject_translocation_to_value': 'Extracellular Sapce'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Biofactors. 2012 Mar;38(2):98-106. doi: 10.1002/biof.199. Epub 2012 Mar 23.',\n",
       "    '22447723'),\n",
       "   'evidence': \"Alzheimer's disease (AD), one of the major causes of disability and mortality in Western societies, is a progressive age-related neurodegenerative disorder. Increasing evidence suggests that the etiology of AD may involve disruptions of zinc (Zn) homeostasis. This review discusses current evidence supporting a potential role of Zn and zinc transporters (ZnTs) in processing of the amyloid beta protein precursor (APP) and amyloid beta (A\\x9f) peptide generation and aggregation.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'deg'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Non-amyloidogenic pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Neurodegener Dis. 2012;10(1-4):60-3. Epub 2011 Dec 7.',\n",
       "    '22156573'),\n",
       "   'evidence': \"Background and Objective: Could a normal - but persistent - stress response to impeded axonal transport lead to late-onset Alzheimer's disease (AD)? Our results offer an affirmative answer, suggesting a mechanism for the abnormal production of amyloid-\\x9f (A\\x9f), triggered by the slowed axonal transport at old age. We hypothesize that A\\x9f precursor protein (APP) is a sensor at the endoplasmic reticulum (ER) that detects, and signals to the nucleus, abnormalities in axonal transport. When persistently activated, due to chronically slowed-down transport, this signaling pathway leads to accumulation of A\\x9f within the ER. Methods and Results: We tested this hypothesis with the neuronal cell line CAD. We show that, normally, a fraction of APP is transported into neurites by recruiting kinesin-1 via the adaptor protein, Fe65. Under conditions that block kinesin-1-dependent transport, APP, Fe65 and kinesin-1 accumulate in the soma, and form a complex at the ER. This complex recruits active c-Jun N-terminal kinase (JNK), which phosphorylates APP at Thr(668). This phosphorylation increases the cleavage of APP by the amyloidogenic pathway, which generates A\\x9f within the ER lumen, and releases Fe65 into the cytoplasm. Part of the released Fe65 translocates into the nucleus, likely to initiate a gene transcription response to arrested transport. Prolonged arrest of kinesin-1-dependent transport could thus lead to accumulation and oligomerization of A\\x9f in the ER. Conclusion: These results support a model where the APP:Fe65 complex is a sensor at the ER for detecting the increased level of kinesin-1 caused by halted transport, which signals to the nucleus, while concomitantly generating an oligomerization-prone pool of A\\x9f in the ER. Our hypothesis could thus explain a pathogenic mechanism in AD.\",\n",
       "   'rel': 'decreases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'UNDEFINED',\n",
       "   'subject_translocation_from_value': 'UNDEFINED',\n",
       "   'subject_translocation_to_namespace': 'UNDEFINED',\n",
       "   'subject_translocation_to_value': 'UNDEFINED'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'ApoE pathway',\n",
       "    'Cholesterol metabolism'),\n",
       "   'citation': ('PubMed', 'PLoS One. 2010 Jan 1;5(1):e8556', '20049331'),\n",
       "   'evidence': 'The low-density lipoprotein receptor (LDLR) has the highest affinity for apoE and plays an important role in brain cholesterol metabolism.These data suggest that increased APP expression and Abeta exposure alters microtubule function, leading to reduced transport of LDLR to the plasma membrane. Consequent deleterious effects on apoE uptake and function will have implications for AD pathogenesis and/or progression',\n",
       "   'rel': 'increases'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'DYRK1A pathway',\n",
       "    'Tumor necrosis factor pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'FEBS J. 2011 Jan;278(2):236-45. doi: 10.1111/j.1742-4658.2010.07955.x.Epub 2010 Dec 13.',\n",
       "    '21156028'),\n",
       "   'evidence': 'DYRK1A phosphorylates APP at Thr688 and enhances APP amyloidogenic cleavage, resulting in increased level of A40/42, formation of toxic A oligomers and deposition of fibrillar amyloid in plaques. Brain amyloidosis contributes to loss of neuronal function and possibly also to neuronal loss. Moreover, elevated levels of A may up-regulate DYRK1A expression and enhance the contribution of overexpressed DYRK1A to neurofibrillary degeneration and -amyloidosis.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'deg'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Endoplasmic reticulum-Golgi protein export pathway',\n",
       "    'Endosomal lysosomal pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):E2077-82. Epub 2012 Jun 18',\n",
       "    '22711829'),\n",
       "   'evidence': 'Depletion of Hrs and Tsg101, acting early in the multivesicular body pathway, retained APP in early endosomes and reduced A(40) production. Conversely, depletion of CHMP6 and VPS4, acting late in the pathway, rerouted endosomal APP to the TGN for enhanced APP processing. We found that VPS35 (retromer)-mediated APP recycling to the TGN was required for efficient A(40) production.',\n",
       "   'rel': 'increases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'MESHCS',\n",
       "   'subject_translocation_from_value': 'Endosomes',\n",
       "   'subject_translocation_to_namespace': 'MESHCS',\n",
       "   'subject_translocation_to_value': 'trans-Golgi Network'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Endoplasmic reticulum-Golgi protein export pathway',\n",
       "    'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):E2077-82. Epub 2012 Jun 18',\n",
       "    '22711829'),\n",
       "   'evidence': 'An interruption of the bidirectional trafficking of APP between the TGN and endosomes, particularly retromer-mediated retrieval of APP from early endosomes to the TGN, resulted in the accumulation of endocytosed APP in early endosomes with reduced APP processing. These data suggest that A(40) is generated predominantly in the TGN, relying on an endocytosed pool of APP recycled from early endosomes to the TGN.',\n",
       "   'rel': 'increases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'MESHCS',\n",
       "   'subject_translocation_from_value': 'Endosomes',\n",
       "   'subject_translocation_to_namespace': 'MESHCS',\n",
       "   'subject_translocation_to_value': 'trans-Golgi Network'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Endosomal lysosomal pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurosci. 2007 Apr 11;27(15):4052-60.',\n",
       "    '17428983'),\n",
       "   'evidence': 'Abeta is a fragment of amyloid-beta precursor protein (APP) generated in neurons by two proteases, beta- and gamma-secretases. APP and beta-secretase, both present on cell surface, are endocytosed into endosomes to produce Abeta. The molecular mechanism by which neurons trigger the production of Abeta is poorly understood. We describe here evidence that the binding of lipid-carrying apolipoprotein E (ApoE) to receptor apolipoprotein E receptor 2 (ApoER2) triggers the endocytosis of APP, beta-secretase, and ApoER2 in neuroblastoma cells, leading to the production of Abeta. This mechanism, mediated by adaptor protein X11alpha or X11beta (X11alpha/beta), whose PTB (phosphotyrosine-binding) domain binds to APP and a newly recognized motif in the cytosolic domain of ApoER2. Isomorphic form ApoE4 triggers the production of more Abeta than by ApoE2 or ApoE3; thus, it may play a role in the genetic risk of ApoE4 for the sporadic AD.',\n",
       "   'rel': 'increases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'MESHCS',\n",
       "   'subject_translocation_from_value': 'Cell Surface Extensions',\n",
       "   'subject_translocation_to_namespace': 'MESHCS',\n",
       "   'subject_translocation_to_value': 'Endosomes'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Synaptic vesicle endocytosis pathway',\n",
       "    'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Alzheimers Dis. 2010;22(3):741-63', '20847424'),\n",
       "   'evidence': 'Cirrito et al. [26] also show that synaptic activity-induced increase in endocytosis drives more APP into the endocytic compartment, ultimately resulting in increased A production and release. A produced in the endocytic pathway is then brought to the cell surface where it is released into the extracellular fluid [70]. Inhibition of endocytosis reduces APP internalization and reduces A production and release in cell lines',\n",
       "   'rel': 'increases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'MESHCS',\n",
       "   'subject_translocation_from_value': 'Cell Membrane',\n",
       "   'subject_translocation_to_namespace': 'MESHCS',\n",
       "   'subject_translocation_to_value': 'Endosomes'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Brain Res Mol Brain Res2001', '11744168'),\n",
       "   'evidence': \"Expression of familial Alzheimer's disease (FAD) mutants of APP in primary neurons causes both intracellular accumulation of the C-terminal beta-secretase cleavage product of APP and increased secretion of Abeta, and eventually results in apoptotic death of the cells.\",\n",
       "   'rel': 'increases'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Endosomal lysosomal pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'International journal of biochemistry and cell biology1999',\n",
       "    '10605825'),\n",
       "   'evidence': \"The formation of beta A4 amyloid in the brains of individuals with Alzheimer's disease requires the proteolytic cleavage of amyloid precursor protein.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'deg'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Endosomal lysosomal pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'International journal of biochemistry and cell biology1999',\n",
       "    '10605825'),\n",
       "   'evidence': 'Several lines of evidence suggest that cathepsin D, the major lysosomal/endosomal aspartic protease, may be involved in this process.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'deg'}),\n",
       " (5,\n",
       "  6,\n",
       "  {'Developmental_Phase__of_patient': ('Developmental stage',),\n",
       "   'Duration_of_Chemical_Exposure': ('Chronic',),\n",
       "   'Encode_Feature_Types': ('Promoter',),\n",
       "   'Species': ('10116',),\n",
       "   'citation': ('PubMed',\n",
       "    'Free Radic Biol Med. 2009 May 1;46(9):1241-9. doi: 10.1016/j.freeradbiomed.2009.02.006. Epub 2009 Feb 23.',\n",
       "    '19245828'),\n",
       "   'evidence': 'hypomethylated APP, individuals, which in turn produces more APP, which is further cleaved to build up A\\x83\\x82 levels',\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (5,\n",
       "  7,\n",
       "  {'Subgraph': ('Raf-MEK-ERK cascade pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2007 May 4;282(18):13833-44. Epub 2007 Feb 21.',\n",
       "    '17314098'),\n",
       "   'evidence': 'Among the different APP-interacting proteins, we focused our interest on the GRB2 adaptor protein, which connects cell surface receptors to intracellular signaling pathways. In this study we provide evidence by co-immunoprecipitation experiments, confocal and electron microscopy, and by fluorescence resonance energy transfer experiments that both APP and presenilin1 interact with GRB2 in vesicular structures at the centrosome of the cell. The final target for these interactions is ERK1,2, which is activated in mitotic centrosomes in a PS1- and APP-dependent manner. These data suggest that both APP and presenilin1 can be part of a common signaling pathway that regulates ERK1,2 and the cell cycle.',\n",
       "   'rel': 'increases'}),\n",
       " (5,\n",
       "  7,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Biochem J. 2013 Mar 1;450(2):333-43. doi: 10.1042/BJ20121100.',\n",
       "    '23167255'),\n",
       "   'evidence': \"APP (amyloid precursor protein) and LRP1 (low-density lipoprotein receptor-related protein 1) have been implicated in the pathogenesis of AD (Alzheimer's disease). They are functionally linked by Fe65, a PTB (phosphotyrosine-binding)-domain-containing adaptor protein that binds to intracellular NPxY-motifs of APP and LRP1, thereby influencing expression levels, cellular trafficking and processing. Additionally, Fe65 has been reported to mediate nuclear signalling in combination with intracellular domains of APP and LRP1. We have previously identified another adaptor protein, GULP1 (engulfment adaptor PTB-domain-containing 1). In the present study we characterize and compare nuclear trafficking and transactivation of GULP1 and Fe65 together with APP and LRP1 and report differential nuclear trafficking of adaptors when APP or LRP1 are co-expressed. The observed effects were additionally supported by a reporter-plasmid-based transactivation assay. The results from the present study indicate that Fe65 might have signalling properties together with APP and LRP1, whereas GULP1 only mediates LRP1 transactivation.\",\n",
       "   'rel': 'increases'}),\n",
       " (5,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Neurobiol Aging2007', '16797788'),\n",
       "   'evidence': \"Amyloid precursor protein (APP) is a widely expressed transmembrane protein of unknown function that is involved in the pathogenesis of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (5,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2007', '17314098'),\n",
       "   'evidence': 'The amyloid precursor protein (APP) and the presenilins 1 and 2 are genetically linked to the development of familial Alzheimer disease.',\n",
       "   'rel': 'association'}),\n",
       " (5,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Neurobiol Dis2005', '15686969'),\n",
       "   'evidence': \"The beta-amyloid precursor protein APP and the microtubule-associated protein Tau play a crucial role in the pathogenesis of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (5, 2936, {'rel': 'reactant'}),\n",
       " (5,\n",
       "  2936,\n",
       "  {'Subgraph': ('Non-amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Mol Brain. 2011 Jan 7;4:3.', '21214928'),\n",
       "   'evidence': 'APP is synthesized in the endoplasmic reticulum (ER) and then transported through the Golgi apparatus to the trans-Golgi-network (TGN) where the highest concentration of APP is found in neurons at steady state. A\\x8e is generated in the ER and Golgi/TGN. From the TGN, APP can be transported in TGN-derived secretory vesicles to the cell surface where it is either cleaved by \\x8e-secretase to produce a soluble molecule, sAPP\\x8e [37], or re-internalized via an endosomal/lysosomal degradation pathway',\n",
       "   'rel': 'decreases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'MESHCS',\n",
       "   'subject_translocation_from_value': 'trans-Golgi Network',\n",
       "   'subject_translocation_to_namespace': 'MESHCS',\n",
       "   'subject_translocation_to_value': 'Cell Surface Extensions'}),\n",
       " (5,\n",
       "  2936,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Cell Sci. 2000 Jun;113 ( Pt 11):1857-70.',\n",
       "    '10806097'),\n",
       "   'evidence': 'Although the requirements for binding of Fe65 and X11 to the GYENPTY motif differ slightly, they are sufficiently overlapping to make it conceivable that these proteins compete for binding to APP. Interestingly, opposite effects on APP processing have been observed after co-expression of APP with either Fe65 or X11. Fe65 overexpression increased the amount of cell-surface-associated APP, as well as the processing of APP to APPs and Ab peptide. By contrast, X11 decreased processing and cellular retention of APP. Thus, the functional balance between the two proteins is important for regulation of APP metabolism and possibly APP function. This balance could be further modified by a third protein, mDAB1 (the mammalian homologue of Disabled), that binds to the same region',\n",
       "   'rel': 'increases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'UNDEFINED',\n",
       "   'subject_translocation_from_value': 'UNDEFINED',\n",
       "   'subject_translocation_to_namespace': 'UNDEFINED',\n",
       "   'subject_translocation_to_value': 'UNDEFINED'}),\n",
       " (5,\n",
       "  2937,\n",
       "  {'Subgraph': ('Gamma secretase pathway',),\n",
       "   'citation': ('PubMed', 'Biochem J. 2012 Mar 1;442(2):413-22.', '22115042'),\n",
       "   'evidence': \"The death of cholinergic neurons in the cerebral cortex and certain subcortical regions is linked to irreversible dementia relevant to AD (Alzheimer's disease). Although multiple studies have shown that expression of a FAD (familial AD)-linked APP (amyloid \\x9f precursor protein) or a PS (presenilin) mutant, but not that of wild-type APP or PS, induced neuronal death by activating intracellular death signals, it remains to be addressed how these signals are interrelated and what the key molecule involved in this process is. In the present study, we show that the PS1-mediated (or possibly the PS2-mediated) signal is essential for the APP-mediated death in a gamma-secretase-independent manner and vice versa. MOCA (modifier of cell adhesion), which was originally identified as being a PS- and Rac1-binding protein, is a common downstream constituent of these neuronal death signals. Detailed molecular analysis indicates that MOCA is a key molecule of the AD-relevant neuronal death signals that links the PS-mediated death signal with the APP-mediated death signal at a point between Rac1 [or Cdc42 (cell division cycle 42)] and ASK1 (apoptosis signal-regulating kinase 1).\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'deg'}),\n",
       " (5,\n",
       "  2937,\n",
       "  {'NervousSystem': ('Axons',),\n",
       "   'Subgraph': ('Amyloidogenic pathway', 'Axonal transport'),\n",
       "   'citation': ('PubMed',\n",
       "    'Hum Mol Genet. 2012 Mar 27. [Epub ahead of print]',\n",
       "    '22434822'),\n",
       "   'evidence': \"Defects in axonal transport are an early pathological feature in Alzheimer's disease and defective APP transport is known to increase A\\x83 production. We show that calsyntenin-1 and APP are co-transported through axons and that siRNA-induced loss of calsyntenin-1 markedly disrupts axonal transport of APP. Thus, perturbation to axonal transport of APP on calsyntenin-1 containing carriers induces alterations to APP processing that increase production of A\\x83. Together, our findings suggest that disruption of calsyntenin-1-associated axonal transport of APP is a pathogenic mechanism in Alzheimer's disease.\",\n",
       "   'rel': 'decreases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'MESHCS',\n",
       "   'subject_translocation_from_value': 'Axons',\n",
       "   'subject_translocation_to_namespace': 'MESHCS',\n",
       "   'subject_translocation_to_value': 'Cell Membrane'}),\n",
       " (5,\n",
       "  2937,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'BMC Neurosci. 2008 Dec 3;9 Suppl 2:S2.',\n",
       "    '19090990'),\n",
       "   'evidence': \"Iron was further demonstrated to modulate expression of the Alzheimer's amyloid precursor holo-protein (APP) by a mechanism similar to that of regulation of ferritin-L and -H mRNA translation through an iron-responsive element (IRE) in their 5' untranslated regions (UTRs). Here, we discuss two aspects of the link between iron and AD, in relation to the recently discovered IRE in the 5'UTR of APP mRNA. The first is the physiological aspect: a compensatory neuroprotective response of amyloid-\\x83 protein (A\\x83) in reducing iron-induced neurotoxicity. Thus, given that A\\x83 possesses iron chelation sites, it is hypothesized that OS-induced intracellular iron may stimulate APP holo-protein translation (via the APP 5'UTR) and subsequently the generation of its cleavage product, A\\x83, as a compensatory response that eventually reduces OS.\",\n",
       "   'rel': 'increases'}),\n",
       " (5,\n",
       "  2937,\n",
       "  {'citation': ('PubMed',\n",
       "    'Curr Alzheimer Res. 2015;12(6):563-71.',\n",
       "    '26027813'),\n",
       "   'evidence': 'In addition, based on timing of changes in cortical thinning and A deposition such as A deposition after cortical thinning; cortical thinning after A deposition, or concurrent A deposition and cortical thinning, we identified three types of relationships between cortical thinning and A deposition: (1) A-associated cortical thinning; (2) A-independent cortical thinning; and (3) A deposition only without cortical thinning. Taken together, these findings suggest that A-weighted cortical thickness values can be used as an objective biomarker of structural changes caused by amyloid pathology in the brain.',\n",
       "   'rel': 'increases'}),\n",
       " (5,\n",
       "  266,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Journal of Neuroscience Research2000', '10797543'),\n",
       "   'evidence': 'Low density lipoprotein receptor-related protein (LRP) participates in the uptake and degradation of several ligands implicated in neuronal pathophysiology including apolipoprotein E (apoE), activated alpha(2) -macroglobulin (alpha(2)M*) and beta-amyloid precursor protein (APP).',\n",
       "   'rel': 'association',\n",
       "   'subject_activity': 'deg'}),\n",
       " (5,\n",
       "  266,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Mol Neurosci2002', '12212791'),\n",
       "   'evidence': 'LDL receptor-related protein , a multifunctional ApoE receptor , binds secreted beta-amyloid precursor protein and mediates its degradation.',\n",
       "   'rel': 'association',\n",
       "   'subject_activity': 'deg'}),\n",
       " (5, 731, {'rel': 'reactant'}),\n",
       " (5,\n",
       "  92,\n",
       "  {'CellStructure': ('Centrosome',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'ApoE was reported to induce Dab1 phosphorylation and ERK1/2 activation and JNK inhibition via LRPs. This pathway depends on the presence of Ca++ influx through the NMDA receptor, but it is independent of Dab1.Overall these data indicate a likely involvement of LRP8 as modulator of A\\x9fPP processing, by affecting its endocytic trafficking and the proportion of A\\x9fPP present in lipid rafts. These events may have consequence on the gamma-secretase-mediated cleavage of A\\x9fPP and on its neurodegeneration-related signaling activity.',\n",
       "   'rel': 'association',\n",
       "   'subject_activity': 'deg'}),\n",
       " (6,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Pharm Pharmacol. 2011 Aug;63(8):1111-8',\n",
       "    '21718295'),\n",
       "   'evidence': \"Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.\",\n",
       "   'rel': 'negativeCorrelation'}),\n",
       " (6,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Pharm Pharmacol. 2011 Aug;63(8):1111-8',\n",
       "    '21718295'),\n",
       "   'evidence': 'Also, fluorescent micrographs showed an inverse relationship between levels of P-gp expression and 5-carboxyfluorescein labelled A (FAM-A42) intracellular accumulation.',\n",
       "   'rel': 'negativeCorrelation'}),\n",
       " (6,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Exp Neurol2010', '20451519'),\n",
       "   'evidence': 'abaton et al. have presented a pmodel of both non-pathological and pathological Abeta activities and suggest potential therapeutic pathways based on their proposed framework of Abeta acting as the signal that induces a kinase cascade, ultimately stimulating transcription factors that upregulate genes such as BACE1.',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2010', '20595388'),\n",
       "   'evidence': 'Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production.',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2010', '20595388'),\n",
       "   'evidence': 'Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Calpastatin-calpain pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2010', '20595388'),\n",
       "   'evidence': 'Interestingly, treatment of cultured primary neurons with amyloid-beta (Abeta) peptides caused an increase in the level of beta-site APP-cleaving enzyme 1 (BACE1), the key enzyme responsible for APP processing and Abeta production. This effect was inhibited by CAST overexpression. ',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  5,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Biophys J. 2012 Mar 21;102(6):1411-7. Epub 2012 Mar 20.',\n",
       "    '22455924'),\n",
       "   'evidence': \"The amyloid precursor protein (APP) is a large, ubiquitous integral membrane protein with a small amyloid-\\x9f (A\\x9f) domain. In the human brain, endosomal processing of APP produces neurotoxic A\\x9f-peptides, which are involved in Alzheimer's disease. Here, we show that the A\\x9f sequence exerts a physiological function when still present in the unprocessed APP molecule. From the extracellular site, A\\x9f concentrates APP molecules into plasmalemmal membrane protein clusters. Moreover, A\\x9f stabilization of clusters is a prerequisite for their targeting to endocytic clathrin structures. Therefore, we conclude that the A\\x9f domain directly mediates a central step in APP trafficking, driving its own conversion into neurotoxic peptides.\",\n",
       "   'object_translocation': True,\n",
       "   'object_translocation_from_namespace': 'UNDEFINED',\n",
       "   'object_translocation_from_value': 'UNDEFINED',\n",
       "   'object_translocation_to_namespace': 'UNDEFINED',\n",
       "   'object_translocation_to_value': 'UNDEFINED',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  5,\n",
       "  {'Developmental_Phase__of_patient': ('Developmental stage',),\n",
       "   'Duration_of_Chemical_Exposure': ('Chronic',),\n",
       "   'Encode_Feature_Types': ('Promoter',),\n",
       "   'Species': ('10116',),\n",
       "   'citation': ('PubMed',\n",
       "    'Free Radic Biol Med. 2009 May 1;46(9):1241-9. doi: 10.1016/j.freeradbiomed.2009.02.006. Epub 2009 Feb 23.',\n",
       "    '19245828'),\n",
       "   'evidence': 'hypomethylated APP, individuals, which in turn produces more APP, which is further cleaved to build up A\\x83\\x82 levels',\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (6,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('Online Resource',\n",
       "    \"Alzheimer's disease - Homo sapiens (human)\",\n",
       "    'hsa05010'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is a chronic disorder that slowly destroys neurons and causes serious cognitive disability. AD is associated with senile plaques and neurofibrillary tangles (NFTs). Amyloid-beta (Abeta), a major component of senile plaques, has various pathological effects on cell and organelle function. The extracellular Abeta oligomers may activate caspases through activation of cell surface death receptors. Alternatively, intracellular Abeta may contribute to pathology by facilitating tau hyper-phosphorylation, disrupting mitochondria function, and triggering calcium dysfunction. To date genetic studies have revealed four genes that may be linked to autosomal dominant or familial early onset AD (FAD). These four genes include: amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2) and apolipoprotein E (ApoE). All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specfically the more amyloidogenic form, Abeta42. FAD-linked PS1 mutation downregulates the unfolded protein response and leads to vulnerability to ER stress.\",\n",
       "   'rel': 'isA'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'CNS Drugs. 2006;20(5):351-72.', '16696577'),\n",
       "   'evidence': \"gamma-Secretase comprises a molecular complex of four integral membrane proteins - presenilin, nicastrin, APH-1 and PEN-2 - and its molecular mechanism remains under extensive scrutiny. The ratio of Abeta(42) over Abeta(40) is increased by familial Alzheimer's disease mutations occurring in the presenilin genes or in APP, near the gamma-secretase cleavage site.\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Clin Neurosci. 2004 Jun;11(5):456-67',\n",
       "    '15177383'),\n",
       "   'evidence': 'The main factors responsible for Abeta formation are mutation of APP or PS1 and PS2 genes or ApoE gene. All mutations associated with APP and PS proteins can lead to an increase in the production of Abeta peptides, specifically the more amyloidogenic form, Abeta42.',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Acetylcholine signaling pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Neurochem Res. 2003 Apr;28(3-4):515-22',\n",
       "    '12675140'),\n",
       "   'evidence': 'In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism.Reduction in cholinergic neurotransmission--experimental or pathological, such as in AD--leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Chemokine pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Neurobiol Learn Mem. 2009 Oct;92(3):356-63. Epub 2009 Apr 24.',\n",
       "    '19394434'),\n",
       "   'evidence': 'These findings suggest that the absence of CCR5 increases expression of CCR2, which leads to the activation of astrocytes causing Abeta deposit, and thereby impairs memory function. These results suggest that CCR5 may be a critical suppressor of the development and progression of AD pathology.',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'FluidAndSecretion': ('Cerebrospinal Fluid',),\n",
       "   'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Mol Psychiatry. 2004 Jul;9(7):705-10', '14699432'),\n",
       "   'evidence': 'Our findings support the notion that CSF tau and Abeta(1-42) may be useful biomarkers in the early identification of AD in MCI subjects.',\n",
       "   'rel': 'biomarkerFor'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Brain Nerve. 2010 Jul;62(7):757-67.', '20675880'),\n",
       "   'evidence': 'Recently, many amyloid PET-positive and cognitively normal subjects were found in PiB-PET studies. PiB-PET studies on healthy subjects have also shown that apolipoprotein (APO) E4 boosts the accumulation of amyloid-beta and may consequently accelerate the pathogenesis of AD',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'FluidAndSecretion': ('Cerebrospinal Fluid',),\n",
       "   'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Rev Med Interne. 2008 Oct;29(10):785-93. Epub 2008 Jun 26.',\n",
       "    '18584921'),\n",
       "   'evidence': 'Amyloid beta-peptide 1-42 (Abeta(1-42)) and hyperphosphorylated tubulin associated unit (tau) isoforms appear to be the most sensitive and specific CSF biomarkers, the combination of these biomarkers depicting the best diagnosis value for AD.',\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neuroinflammation. 2011 Nov 2;8:150.',\n",
       "    '22047170'),\n",
       "   'evidence': \"-Amyloid (A) plays a central role in Alzheimer's disease (AD) pathogenesis. Neurons are major sources of A in the brain. However, astrocytes outnumber neurons by at least five-fold. Thus, even a small level of astrocytic A production could make a significant contribution to A burden in AD. Moreover, activated astrocytes may increase A generation. -Site APP cleaving enzyme 1 (BACE1) cleavage of amyloid precursor protein (APP) initiates A production.\",\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'Response to oxidative stress pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurosci. 2006 May 10;26(19):5167-79',\n",
       "    '16687508'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'Response to oxidative stress pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurosci. 2006 May 10;26(19):5167-79',\n",
       "    '16687508'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    '2010 Apr 13;107(15):6557-8. doi: 10.1073/pnas.1002555107.',\n",
       "    '20385830'),\n",
       "   'evidence': 'The pathogenesis of AD begins with impaired synaptic function, which may result from the accumulation of amyloid-\\x8e (A\\x8e) peptide (5\\x828). For many years, researchers have focused on the insoluble deposits of amyloid fibrils as the leading cause of memory loss and as the culprit of AD. More recent findings, however, suggest soluble A\\x8e oligomers may be the cause of memory loss, especially in the early stages of AD, because A\\x8e oligomers inhibit long-term potentiation in neurons, a well-adopted experimental paradigm for learning and memory (6, 9). A\\x8e is produced from amyloid precursor protein (APP) by serial proteolytic reactions catalyzed by \\x8e-site of APP cleaving enzyme (BACE) and a multiprotein complex \\x8e-secretase, in which presenilin is likely the catalytic component ',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Cell Adh Migr. 2011 Jul-Aug;5(4):280-92. Epub 2011 Jul 1.',\n",
       "    '21785276'),\n",
       "   'evidence': 'The amyloid-beta (A\\x8e) peptide is the derivative of amyloid precursor protein (APP) generated through sequential proteolytic processing by \\x8e- and \\x8e-secretases. Excessive accumulation of A\\x8e, the main constituent of amyloid plaques, has been implicated in the etiology of Alzheimer disease (AD). ',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'DiseaseState': ('Mild AD',),\n",
       "   'FDASTATUS': ('Phase 3',),\n",
       "   'Subgraph': ('Inflammatory response pathway',\n",
       "    'Non-amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'J Alzheimers Dis. 2009;17(4):757-60', '19542625'),\n",
       "   'evidence': \"There has been a lot of disappointment surrounding the recent failure of the largest ever study in patients with Alzheimer's disease (AD) with tarenflurbil. A straightforward explanation of this failure is that the gamma-secretase is not the right target for therapy or that, in general, blocking A beta does not produce clinical benefits in AD\",\n",
       "   'rel': 'causesNoChange'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'CardiovascularSystem': ('Microvessels',),\n",
       "   'MeSHDisease': ('Hypertension',\n",
       "    'Alzheimer Disease',\n",
       "    'Cerebral Amyloid Angiopathy'),\n",
       "   'NervousSystem': ('Cerebrum',),\n",
       "   'Subgraph': ('Nitric oxide pathway', 'Non-amyloidogenic pathway'),\n",
       "   'Tissue': ('Endothelium',),\n",
       "   'citation': ('PubMed', 'Med Hypotheses. 2014 Feb;82(2):145-50', '24332564'),\n",
       "   'evidence': 'First, Pin1 inhibits the production of A, and enhances the activity of eNOS. Second, A and eNOS form a mutual inhibition system. Third, the well-balanced feedback signaling loop avoids the development of AD, HTN, and CAA by inhibiting the frequent pathological characteristics of these diseases, including A deposition in cerebral microvessels and cerebral microbleeds.',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'ApoE pathway'),\n",
       "   'citation': ('PubMed', 'Am J Pathol2004', '15331417'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulation of beta-amyloid (Abeta).\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'ApoE pathway'),\n",
       "   'citation': ('PubMed', 'Ann N Y Acad Sci2006', '17185504'),\n",
       "   'evidence': \"Amyloid-beta peptide (Abeta) production and accumulation in the brain is a central event in the pathogenesis of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Acta Biochim Pol2004', '15218540'),\n",
       "   'evidence': 'According to the amyloid hypothesis, accumulation of Abeta is the primary influence driving AD pathogenesis.',\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2005', '16027115'),\n",
       "   'evidence': 'Amyloid-beta peptides (Abeta) are widely presumed to play a causal role in Alzheimer disease.',\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Microbiol2006', '17205046'),\n",
       "   'evidence': \"Amyloid beta-peptide (Abeta), which is a product of the proteolytic effect of beta-secretase (BACE) on an amyloid precursor protein, is closely associated with Alzheimer's disease (AD) pathogenesis.\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Proc Natl Acad Sci U S A2007', '17360493'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulation of the neurotoxic peptide amyloid-beta (Abeta), which is produced by sequential cleavage of amyloid precursor protein (APP) by the aspartyl protease beta-secretase and the presenilin-dependent protease gamma-secretase.\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Scand J Clin Lab Invest2009', '19199126'),\n",
       "   'evidence': \"Amyloid-beta (Abeta) is either directly involved in the pathogenesis of Alzheimer's disease (AD) or tightly correlated with other primary pathogenic factors.\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Curr Alzheimer Res2009', '19355846'),\n",
       "   'evidence': \"Accumulation of beta-amyloid peptide (Abeta) in the brain is a primary influence driving Alzheimer's disease (AD) pathogenesis.\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Exp Gerontol2010', '19698775'),\n",
       "   'evidence': 'Clearly, AD is associated with accumulation of amyloid beta (Abeta) in the brain.',\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Cholesterol metabolism'),\n",
       "   'citation': ('PubMed', 'Biochem Biophys Res Commun2010', '20138836'),\n",
       "   'evidence': \"It has been suggested that cholesterol may pmodulate amyloid-beta (Abeta) formation, a causative factor of Alzheimer's disease (AD), by regulating distribution of the three key proteins in the pathogenesis of AD (beta-amyloid precursor protein (APP), beta-secretase (BACE1) and/or presenilin 1 (PS1)) within lipid rafts.\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'J Alzheimers Dis2010', '20157255'),\n",
       "   'evidence': \"Accumulation of amyloid-beta (Abeta) peptide and deposition of hyperphosphorylated tau protein are two major pathological hallmarks of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2003', '12473667'),\n",
       "   'evidence': 'BACE1 is a membrane-bound aspartic protease that cleaves the amyloid precursor protein (APP) at the beta-secretase site, a critical step in the Alzheimer disease pathogenesis.',\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Anal Biochem2003', '14622952'),\n",
       "   'evidence': \"The cerebral deposition of amyloid beta-peptide (Abeta) is a major factor in the etiology of Alzheimer's disease. beta-Secretase (BACE) initiates the generation of Abeta by cleaving the amyloid precursor protein at the beta-site and is therefore a prime target for therapeutic intervention.\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Structure2005', '16216580'),\n",
       "   'evidence': \"The aspartic protease beta-secretase (BACE) cleaves the amyloid precursor protein into a 42 residue beta-peptide, which is the principal biochemical marker of Alzheimer's disease.\",\n",
       "   'rel': 'biomarkerFor'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurosci2005', '16306400'),\n",
       "   'evidence': \"Beta-secretase [beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1)] is the key rate-limiting enzyme for the production of the beta-amyloid (Abeta) peptide involved in the pathogenesis of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Anal Bioanal Chem2007', '17541560'),\n",
       "   'evidence': \"The amyloid beta (Abeta) peptide is responsible for toxic amyloid plaque formation and is central to the aetiology of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Mol Psychiatry2009', '18813209'),\n",
       "   'evidence': \"Elevation of intracranial soluble amyloid-beta (Abeta) levels has been implicated in the pathogenesis of Alzheimer's disease (AD).\",\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'PLoS One2013', '23577068'),\n",
       "   'evidence': 'PrP(C) decreases amyloid-beta (Abeta) production, which is involved in AD pathogenesis, by inhibiting beta-secretase (BACE1) activity.',\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Journal of Biological Chemistry1996', '8626687'),\n",
       "   'evidence': \"A beta is thought to play a role in the pathogenesis of Alzheimer's disease, and, hence, considerable effort has been invested in defining the means by which A beta is generated from the APPs.\",\n",
       "   'rel': 'association'}),\n",
       " (6,\n",
       "  7,\n",
       "  {'NervousSystem': ('Brain',),\n",
       "   'Species': ('10090',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Mol Neurosci. 2008;34(1):1-7. Epub 2007 Apr 17.',\n",
       "    '18157652'),\n",
       "   'evidence': 'developmental exposure of rodents to the heavy metal lead (Pb) increases APP (amyloid precursor protein) and Abeta production later in the aging brain',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  266,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2005', '15772078'),\n",
       "   'evidence': 'Increasing evidence suggests that the low density lipoprotein receptor-related protein ( LRP ) affects the processing of amyloid precursor protein ( APP ) and amyloid beta ( Abeta ) protein production as well as mediates the clearance of Abeta from the brain.',\n",
       "   'rel': 'association',\n",
       "   'subject_activity': 'deg'}),\n",
       " (6,\n",
       "  266,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Nat Med2007', '17694066'),\n",
       "   'evidence': \"Recombinant LRP cluster IV ( LRP-IV ) bound Abeta in plasma in mice and Alzheimer 's disease-affected humans with compromised sLRP-mediated AAbetabinding , and reduced Abeta-related pathology and dysfunction in a mouse pmodel of Alzheimer disease , suggesting that LRP-IV can effectively replace native sLRP and clear AAbeta\",\n",
       "   'rel': 'association',\n",
       "   'subject_activity': 'deg'}),\n",
       " (6,\n",
       "  155,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Tumor necrosis factor pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'FEBS J. 2011 Jan;278(2):236-45. doi: 10.1111/j.1742-4658.2010.07955.x.Epub 2010 Dec 13.',\n",
       "    '21156028'),\n",
       "   'evidence': 'DYRK1A phosphorylates APP at Thr688 and enhances APP amyloidogenic cleavage, resulting in increased level of A40/42, formation of toxic A oligomers and deposition of fibrillar amyloid in plaques. Brain amyloidosis contributes to loss of neuronal function and possibly also to neuronal loss. Moreover, elevated levels of A may up-regulate DYRK1A expression and enhance the contribution of overexpressed DYRK1A to neurofibrillary degeneration and -amyloidosis.',\n",
       "   'rel': 'increases'}),\n",
       " (6,\n",
       "  155,\n",
       "  {'NervousSystem': ('Neurons',),\n",
       "   'Species': ('10116',),\n",
       "   'citation': ('PubMed', 'J Neurochem. 2008 Jul;106(1):392-404', '18397369'),\n",
       "   'evidence': 'In this study, we show that at nanomolar-low micromolar concentrations, etazolate, a selective GABA(A) receptor modulator, stimulates sAPPalpha production in rat cortical neurons and in guinea pig brains. Etazolate (20 nM-2 microM) dose-dependently protected rat cortical neurons against Abeta-induced toxicity. The neuroprotective effects of etazolate were fully blocked by GABA(A) receptor antagonists indicating that this neuroprotection was due to GABA(A) receptor signalling. This indicating that etazolate exerts its neuroprotective effect via sAPPalpha induction.',\n",
       "   'rel': 'association'}),\n",
       " (263,\n",
       "  279,\n",
       "  {'Subgraph': ('Notch pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Another relevant role for PSs is Notch processing. Notch signaling is involved in cell fate regulation, cell differentiation, proliferation, and apoptosis as well as neurodegeneration. Notch is a membrane receptor whose C-terminal domain (NICD), upon interaction with appropriate ligands, translocates into the nucleus where it activates the CSL family of transcription factors. NICD formation depends on gamma-secretase complex as the AICD fragment of A\\x9fPP. PSs play a role in apoptosis, since FAD mutants cause cell death or induce secondary events that may lead to apoptosis .Animals, in which PS1 and PS2 genes are deleted, show deficit in learning, memory, synaptic function and neuronal death. The processes beneath these effects are unknown, but the findings that PS1 interacts with antiapoptotic member of Bcl-2 family might indicate a possible mechanism.',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'act'}),\n",
       " (263,\n",
       "  279,\n",
       "  {'Subgraph': ('Notch pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurochem. 2010 Apr;113(1):262-74. doi:10.1111/j.1471-4159.2010.06603.x. Epub 2010 Jan 20.',\n",
       "    '20089128'),\n",
       "   'evidence': \"The amyloid precursor protein is a ubiquitously expressed transmembrane protein that has been long implicated in the pathogenesis of Alzheimer's disease but its normal biological function has remained elusive despite extensive effort. We have previously reported the identification of Notch2 as an amyloid precursor protein interacting protein in E18 rat neurons. Here, we sought to reveal the physiologic consequences of this interaction. We report a functional relationship between amyloid precursor protein and Notch1, which does not affect Delta ligand binding. First, we observed interactions between the amyloid precursor protein and Notch in mouse embryonic stem cells lacking both presenilin 1 and presenilin 2, the active proteolytic components of the gamma-secretase complex, suggesting that these two transmembrane proteins can interact in the absence of presenilin. Next, we demonstrated that the amyloid precursor protein affects Notch signaling by using Notch-dependent luciferase assays in two cell lines, the human embryonic kidney 293 and the monkey kidney, COS7. We found that the amyloid precursor protein exerts opposing effects on Notch signaling in human embryonic kidney 293 vs. COS7 cells. Finally, we show that more Notch Intracellular Domain is found in the nucleus in the presence of exogenous amyloid precursor protein or its intracellular domain, suggesting the mechanism by which the amyloid precursor protein affects Notch signaling in certain cells. Our results provide evidence of potentially important communications between the amyloid precursor protein and Notch.\",\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'act'}),\n",
       " (266,\n",
       "  2937,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Curr Alzheimer Res. 2008 Feb;5(1):15-25',\n",
       "    '18288927'),\n",
       "   'evidence': 'it has been demonstrated that LRP1 might bind to APP independent of the KPI domain in APP. This APP - LRP1 interaction is facilitated through a trimeric complex of APP-FE65-LRP1, which has a functional role in APP processing. Along with LRP1, APP is transported from the early secretory compartments to the cell surface and subsequently internalised into the endosomal / lysosomal compartments. Recent investigations indicate that ApoER2 and SorLA fulfil a similar role in shifting APP localisation in the cell, which affects APP processing and the production of the APP derived amyloid beta-peptide (Abeta)',\n",
       "   'rel': 'decreases',\n",
       "   'subject_activity': 'tport'}),\n",
       " (266,\n",
       "  2937,\n",
       "  {'DigestiveSystem': ('Liver',),\n",
       "   'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Curr Alzheimer Res. 2008 Feb;5(1):15-25',\n",
       "    '18288927'),\n",
       "   'evidence': 'Following this export Abeta is degraded in the liver, where LRP1 potentially conducts the removal of Abeta from the blood stream',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_activity': 'tport'}),\n",
       " (266,\n",
       "  5,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Journal of Neuroscience Research2000', '10797543'),\n",
       "   'evidence': 'Low density lipoprotein receptor-related protein (LRP) participates in the uptake and degradation of several ligands implicated in neuronal pathophysiology including apolipoprotein E (apoE), activated alpha(2) -macroglobulin (alpha(2)M*) and beta-amyloid precursor protein (APP).',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'association'}),\n",
       " (266,\n",
       "  5,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Mol Neurosci2002', '12212791'),\n",
       "   'evidence': 'LDL receptor-related protein , a multifunctional ApoE receptor , binds secreted beta-amyloid precursor protein and mediates its degradation.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'association'}),\n",
       " (266,\n",
       "  6,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2005', '15772078'),\n",
       "   'evidence': 'Increasing evidence suggests that the low density lipoprotein receptor-related protein ( LRP ) affects the processing of amyloid precursor protein ( APP ) and amyloid beta ( Abeta ) protein production as well as mediates the clearance of Abeta from the brain.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'association'}),\n",
       " (266,\n",
       "  6,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Nat Med2007', '17694066'),\n",
       "   'evidence': \"Recombinant LRP cluster IV ( LRP-IV ) bound Abeta in plasma in mice and Alzheimer 's disease-affected humans with compromised sLRP-mediated AAbetabinding , and reduced Abeta-related pathology and dysfunction in a mouse pmodel of Alzheimer disease , suggesting that LRP-IV can effectively replace native sLRP and clear AAbeta\",\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'association'}),\n",
       " (266,\n",
       "  7,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Biochem J. 2013 Mar 1;450(2):333-43. doi: 10.1042/BJ20121100.',\n",
       "    '23167255'),\n",
       "   'evidence': \"APP (amyloid precursor protein) and LRP1 (low-density lipoprotein receptor-related protein 1) have been implicated in the pathogenesis of AD (Alzheimer's disease). They are functionally linked by Fe65, a PTB (phosphotyrosine-binding)-domain-containing adaptor protein that binds to intracellular NPxY-motifs of APP and LRP1, thereby influencing expression levels, cellular trafficking and processing. Additionally, Fe65 has been reported to mediate nuclear signalling in combination with intracellular domains of APP and LRP1. We have previously identified another adaptor protein, GULP1 (engulfment adaptor PTB-domain-containing 1). In the present study we characterize and compare nuclear trafficking and transactivation of GULP1 and Fe65 together with APP and LRP1 and report differential nuclear trafficking of adaptors when APP or LRP1 are co-expressed. The observed effects were additionally supported by a reporter-plasmid-based transactivation assay. The results from the present study indicate that Fe65 might have signalling properties together with APP and LRP1, whereas GULP1 only mediates LRP1 transactivation.\",\n",
       "   'rel': 'increases'}),\n",
       " (266,\n",
       "  7,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway', 'ApoE pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Neurobiol Aging. 2012 Mar;33(3):628.e1-628.e14. doi: 10.1016/j.neurobiolaging.2011.04.010. Epub 2011 Jun 15.',\n",
       "    '21676498'),\n",
       "   'evidence': \"Inheritance of the \\x83\\x824 allele of apolipoprotein E (ApoE) is the only confirmed and consistently replicated risk factor for late onset Alzheimer's disease (AD). ApoE is also a key ligand for low-density lipoprotein (LDL) receptor-related protein (LRP), a major neuronal low-density lipoprotein receptor. ApoE and LRP mRNA expression was significantly elevated in the postmortem inferior temporal gyrus (area 20) and the hippocampus from individuals with dementia compared with those with intact cognition. In addition to their strong association with the progression of cognitive dysfunction, LRP and ApoE mRNA levels were also positively correlated with increasing neuropathological hallmarks of AD. Additionally, Western blot analysis of ApoE protein expression in the hippocampus showed that the differential expression observed at the transcriptional level is also reflected at the protein level. Given the critical role played by LRP and ApoE in amyloid beta (A\\x83\\x82) and cholesterol trafficking, increased expression of LRP and ApoE may not only disrupt cholesterol homeostasis but may also contribute to some of the neurobiological features of AD, including plaque deposition.\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (279,\n",
       "  2,\n",
       "  {'Subgraph': ('Notch pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2003 May 30;278(22):20117-23. Epub 2003 Mar 14.',\n",
       "    '12639958'),\n",
       "   'evidence': \"PEN-2 is an integral membrane protein that is a necessary component of the gamma-secretase complex, which is central in the pathogenesis of Alzheimer's disease and is also required for Notch signaling. In the absence of PEN-2, Notch signaling fails to guide normal development in Caenorhabditis elegans, and amyloid beta peptide is not generated from the amyloid precursor protein\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (279,\n",
       "  155,\n",
       "  {'Subgraph': ('Notch pathway', 'Apoptosis pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Another relevant role for PSs is Notch processing. Notch signaling is involved in cell fate regulation, cell differentiation, proliferation, and apoptosis as well as neurodegeneration. Notch is a membrane receptor whose C-terminal domain (NICD), upon interaction with appropriate ligands, translocates into the nucleus where it activates the CSL family of transcription factors. NICD formation depends on gamma-secretase complex as the AICD fragment of A\\x9fPP. PSs play a role in apoptosis, since FAD mutants cause cell death or induce secondary events that may lead to apoptosis .Animals, in which PS1 and PS2 genes are deleted, show deficit in learning, memory, synaptic function and neuronal death. The processes beneath these effects are unknown, but the findings that PS1 interacts with antiapoptotic member of Bcl-2 family might indicate a possible mechanism.',\n",
       "   'rel': 'association'}),\n",
       " (155,\n",
       "  279,\n",
       "  {'Subgraph': ('Notch pathway', 'Apoptosis pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Another relevant role for PSs is Notch processing. Notch signaling is involved in cell fate regulation, cell differentiation, proliferation, and apoptosis as well as neurodegeneration. Notch is a membrane receptor whose C-terminal domain (NICD), upon interaction with appropriate ligands, translocates into the nucleus where it activates the CSL family of transcription factors. NICD formation depends on gamma-secretase complex as the AICD fragment of A\\x9fPP. PSs play a role in apoptosis, since FAD mutants cause cell death or induce secondary events that may lead to apoptosis .Animals, in which PS1 and PS2 genes are deleted, show deficit in learning, memory, synaptic function and neuronal death. The processes beneath these effects are unknown, but the findings that PS1 interacts with antiapoptotic member of Bcl-2 family might indicate a possible mechanism.',\n",
       "   'rel': 'association'}),\n",
       " (155,\n",
       "  6,\n",
       "  {'NervousSystem': ('Neurons',),\n",
       "   'Species': ('10116',),\n",
       "   'citation': ('PubMed', 'J Neurochem. 2008 Jul;106(1):392-404', '18397369'),\n",
       "   'evidence': 'In this study, we show that at nanomolar-low micromolar concentrations, etazolate, a selective GABA(A) receptor modulator, stimulates sAPPalpha production in rat cortical neurons and in guinea pig brains. Etazolate (20 nM-2 microM) dose-dependently protected rat cortical neurons against Abeta-induced toxicity. The neuroprotective effects of etazolate were fully blocked by GABA(A) receptor antagonists indicating that this neuroprotection was due to GABA(A) receptor signalling. This indicating that etazolate exerts its neuroprotective effect via sAPPalpha induction.',\n",
       "   'rel': 'association'}),\n",
       " (155,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'Response to oxidative stress pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurosci. 2006 May 10;26(19):5167-79',\n",
       "    '16687508'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (155,\n",
       "  7,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'Response to oxidative stress pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurosci. 2006 May 10;26(19):5167-79',\n",
       "    '16687508'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia\",\n",
       "   'rel': 'association'}),\n",
       " (155,\n",
       "  7,\n",
       "  {'Subgraph': ('Acetylcholine signaling pathway',),\n",
       "   'citation': ('Online Resource', 'AD_HBP', 'DB00989'),\n",
       "   'evidence': \"Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (155,\n",
       "  7,\n",
       "  {'citation': ('PubMed', 'J Neurosci2009', '19458225'),\n",
       "   'evidence': \"The neuronal loss associated with Alzheimer's disease (AD) affects areas of the brain that are vital to cognition.\",\n",
       "   'rel': 'association'}),\n",
       " (155,\n",
       "  7,\n",
       "  {'citation': ('PubMed',\n",
       "    'Neurochem Res. 2015 Feb;40(2):380-8. doi: 10.1007/s11064-014-1391-2. Epub 2014 Jul 27.',\n",
       "    '25064045'),\n",
       "   'evidence': 'Mn neurotoxicity is also known to contribute to the development of multiple neurodegenerative disorders including AD,',\n",
       "   'rel': 'increases'}),\n",
       " (92,\n",
       "  5,\n",
       "  {'CellStructure': ('Centrosome',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'ApoE was reported to induce Dab1 phosphorylation and ERK1/2 activation and JNK inhibition via LRPs. This pathway depends on the presence of Ca++ influx through the NMDA receptor, but it is independent of Dab1.Overall these data indicate a likely involvement of LRP8 as modulator of A\\x9fPP processing, by affecting its endocytic trafficking and the proportion of A\\x9fPP present in lipid rafts. These events may have consequence on the gamma-secretase-mediated cleavage of A\\x9fPP and on its neurodegeneration-related signaling activity.',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'association'}),\n",
       " (92,\n",
       "  7,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Microsc Res Tech. 2000 Aug 15;50(4):268-72.',\n",
       "    '10936878'),\n",
       "   'evidence': 'polymorphisms in three other genes (among others), apolipoprotein E (apoE), alpha2-macroglobulin (alpham), and the low density lipoprotein receptor-related protein (LRP), are implicated to contribute to AD pathogenesis',\n",
       "   'rel': 'increases'}),\n",
       " (92,\n",
       "  7,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Role of LPR8 activation in normal brain functioning and in neurodegeneration during AD.',\n",
       "   'rel': 'association',\n",
       "   'subject_activity': 'act'}),\n",
       " (731, 6, {'rel': 'product'}),\n",
       " (289,\n",
       "  2937,\n",
       "  {'NervousSystem': ('Brain',),\n",
       "   'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Mol Cell Neurosci. 2010 Nov;45(3):306-15. Epub 2010 Jul 14.',\n",
       "    '20637285'),\n",
       "   'evidence': 'In the brain, megalin is expressed in brain capillaries, ependymal cells and choroid plexus, where it participates in the clearance of brain amyloid \\x8e-peptide (A\\x8e) complex.Additionally, given that FE65 mediates the interaction between the low density lipoprotein receptor-related protein-1 and the amyloid precursor protein (APP) to modulate the rate of APP internalization from the cell surface, we hypothesize that megalin could also interact with APP in neurons.',\n",
       "   'rel': 'directlyDecreases'}),\n",
       " (611,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway',\n",
       "    'Amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'Neurosci Bull. 2010 Aug;26(4):338-44.', '20651816'),\n",
       "   'evidence': \"It is believed that amyloid-beta peptide (Abeta) plays a central role in the pathogenesis of Alzheimer's disease (AD). Thus, the process of amyloid precursor protein (APP) cleavage is a key event and has raised much attention in the field of AD research. It is proposed that APP, beta- and gamma-secretases are all located on the lipid raft, and the meeting of them is an indispensable step for Abeta generation. Endocytosis can lead to clustering of APP, beta- and gamma-secretases from separate smaller lipid rafts into a larger one. On the other hand, for myristoylated alanine-rich C kinase substrate (MARCKS), phosphorylation by protein kinase C (PKC) or interaction with Ca(2+) can lead to its release from membrane into cytoplasm. This process induces the release of actins and phosphatidylinositol 4, 5-bisphosphate (PIP2), which are important factors for endocytosis. Thus, the present review proposes that MARCKS may be implicated in Abeta generation, by modulating free PIP2 level and actin movement, causing endocytosis\",\n",
       "   'rel': 'directlyIncreases'}),\n",
       " (2212,\n",
       "  2,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Phosphatidylinositol 3 pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurochem. 2007 Aug;102(3):848-57. Epub 2007 Apr 16',\n",
       "    '17437536'),\n",
       "   'evidence': \"We previously showed that some familial Alzheimer's disease PS mutations cause increased basal and acetylcholine muscarinic receptor-stimulated phospholipase C (PLC) activity which was gamma-secretase dependent.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  2,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Phosphatidylinositol 3 pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurochem. 2007 Aug;102(3):848-57. Epub 2007 Apr 16',\n",
       "    '17437536'),\n",
       "   'evidence': \"We previously showed that some familial Alzheimer's disease PS mutations cause increased basal and acetylcholine muscarinic receptor-stimulated phospholipase C (PLC) activity which was gamma-secretase dependent.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Dev Neurosci. 2004 Nov;22(7):467-74.',\n",
       "    '15465276'),\n",
       "   'evidence': 'BACE1 is primarily expressed by neurons and increased BACE1 protein concentrations and enzymatic activities have been reported in the brains of AD patients. However, there is accumulating evidence that, in addition to neurons, reactive astrocytes are capable of expressing BACE1 and, therefore, may contribute to beta-amyloid plaque formation. This suggests that conditions accompanied by chronic astrocyte activation may contribute to developing AD.',\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'miRNA pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6415-20. doi: 10.1073/pnas.0710263105. Epub 2008 Apr 23.',\n",
       "    '18434550'),\n",
       "   'evidence': \"The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.We show here that miR-29a, -29b-1, and -9 can regulate BACE1 expression in vitro.\",\n",
       "   'rel': 'increases'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'citation': ('PubMed', 'J Neurochem. 2008 Jul;106(1):392-404', '18397369'),\n",
       "   'evidence': 'The proteolytic cleavage of the amyloid precursor protein (APP) through the alpha-secretase pathway decreases in AD, concurrent with cognitive impairment. This APP cleavage occurs within the beta-amyloid peptide (Abeta) sequence, precluding formation of amyloidogenic peptides and leading to the release of the soluble N-terminal APP fragment (sAPPalpha) which is neurotrophic and procognitive.',\n",
       "   'object_activity': 'pep',\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Nuclear factor Kappa beta pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': \"Increased NF-B signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Species': ('9606',),\n",
       "   'Subgraph': ('Beta secretase pathway', 'Nuclear factor Kappa beta pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': \"Elevated levels of -site APP cleaving enzyme 1 (BACE1) were found in the brain of some sporadic Alzheimer's disease (AD) patients; however, the underlying mechanism is unknown.\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Plaque, Amyloid',),\n",
       "   'NervousSystem': ('Brain',),\n",
       "   'Species': ('9606',),\n",
       "   'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90',\n",
       "    '21329555'),\n",
       "   'evidence': 'In this report we found that both BACE1 and NF-B p65 levels were significantly increased in the brains of AD patients.',\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'MeSHDisease': ('Alzheimer Disease',),\n",
       "   'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed', 'J Med Chem. 2012 Nov 8;55(21):9224-39', '22984865'),\n",
       "   'evidence': \"-Secretase 1 (BACE-1) is an attractive therapeutic target for the treatment and prevention of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2004', '15452128'),\n",
       "   'evidence': 'Our studies demonstrate, for the first time, that pmodulation of BACE1 activity may play a significant role in AD pathogenesis in vivo.',\n",
       "   'object_activity': 'pep',\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Mol Cell Neurosci2004', '15080893'),\n",
       "   'evidence': \"BACE is an aspartyl protease that cleaves the amyloid precursor protein (APP) at the beta-secretase cleavage site and is involved in Alzheimer's disease.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway',),\n",
       "   'citation': ('PubMed', 'FASEB J2008', '18413858'),\n",
       "   'evidence': \"BACE1 is a promising therapeutic and preventive target for Alzheimer's disease because it is essential for amyloid deposition.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  5,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Neurobiol Aging2007', '16797788'),\n",
       "   'evidence': \"Amyloid precursor protein (APP) is a widely expressed transmembrane protein of unknown function that is involved in the pathogenesis of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  5,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Gamma secretase pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2007', '17314098'),\n",
       "   'evidence': 'The amyloid precursor protein (APP) and the presenilins 1 and 2 are genetically linked to the development of familial Alzheimer disease.',\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  5,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Neurobiol Dis2005', '15686969'),\n",
       "   'evidence': \"The beta-amyloid precursor protein APP and the microtubule-associated protein Tau play a crucial role in the pathogenesis of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'CNS Drugs. 2006;20(5):351-72.', '16696577'),\n",
       "   'evidence': \"gamma-Secretase comprises a molecular complex of four integral membrane proteins - presenilin, nicastrin, APH-1 and PEN-2 - and its molecular mechanism remains under extensive scrutiny. The ratio of Abeta(42) over Abeta(40) is increased by familial Alzheimer's disease mutations occurring in the presenilin genes or in APP, near the gamma-secretase cleavage site.\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'FluidAndSecretion': ('Cerebrospinal Fluid',),\n",
       "   'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Rev Med Interne. 2008 Oct;29(10):785-93. Epub 2008 Jun 26.',\n",
       "    '18584921'),\n",
       "   'evidence': 'Amyloid beta-peptide 1-42 (Abeta(1-42)) and hyperphosphorylated tubulin associated unit (tau) isoforms appear to be the most sensitive and specific CSF biomarkers, the combination of these biomarkers depicting the best diagnosis value for AD.',\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'Response to oxidative stress pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurosci. 2006 May 10;26(19):5167-79',\n",
       "    '16687508'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'Response to oxidative stress pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurosci. 2006 May 10;26(19):5167-79',\n",
       "    '16687508'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'ApoE pathway'),\n",
       "   'citation': ('PubMed', 'Am J Pathol2004', '15331417'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulation of beta-amyloid (Abeta).\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'ApoE pathway'),\n",
       "   'citation': ('PubMed', 'Ann N Y Acad Sci2006', '17185504'),\n",
       "   'evidence': \"Amyloid-beta peptide (Abeta) production and accumulation in the brain is a central event in the pathogenesis of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Acta Biochim Pol2004', '15218540'),\n",
       "   'evidence': 'According to the amyloid hypothesis, accumulation of Abeta is the primary influence driving AD pathogenesis.',\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2005', '16027115'),\n",
       "   'evidence': 'Amyloid-beta peptides (Abeta) are widely presumed to play a causal role in Alzheimer disease.',\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Microbiol2006', '17205046'),\n",
       "   'evidence': \"Amyloid beta-peptide (Abeta), which is a product of the proteolytic effect of beta-secretase (BACE) on an amyloid precursor protein, is closely associated with Alzheimer's disease (AD) pathogenesis.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Proc Natl Acad Sci U S A2007', '17360493'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulation of the neurotoxic peptide amyloid-beta (Abeta), which is produced by sequential cleavage of amyloid precursor protein (APP) by the aspartyl protease beta-secretase and the presenilin-dependent protease gamma-secretase.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Scand J Clin Lab Invest2009', '19199126'),\n",
       "   'evidence': \"Amyloid-beta (Abeta) is either directly involved in the pathogenesis of Alzheimer's disease (AD) or tightly correlated with other primary pathogenic factors.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Curr Alzheimer Res2009', '19355846'),\n",
       "   'evidence': \"Accumulation of beta-amyloid peptide (Abeta) in the brain is a primary influence driving Alzheimer's disease (AD) pathogenesis.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Exp Gerontol2010', '19698775'),\n",
       "   'evidence': 'Clearly, AD is associated with accumulation of amyloid beta (Abeta) in the brain.',\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway', 'Cholesterol metabolism'),\n",
       "   'citation': ('PubMed', 'Biochem Biophys Res Commun2010', '20138836'),\n",
       "   'evidence': \"It has been suggested that cholesterol may pmodulate amyloid-beta (Abeta) formation, a causative factor of Alzheimer's disease (AD), by regulating distribution of the three key proteins in the pathogenesis of AD (beta-amyloid precursor protein (APP), beta-secretase (BACE1) and/or presenilin 1 (PS1)) within lipid rafts.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'J Alzheimers Dis2010', '20157255'),\n",
       "   'evidence': \"Accumulation of amyloid-beta (Abeta) peptide and deposition of hyperphosphorylated tau protein are two major pathological hallmarks of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Biol Chem2003', '12473667'),\n",
       "   'evidence': 'BACE1 is a membrane-bound aspartic protease that cleaves the amyloid precursor protein (APP) at the beta-secretase site, a critical step in the Alzheimer disease pathogenesis.',\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'Anal Biochem2003', '14622952'),\n",
       "   'evidence': \"The cerebral deposition of amyloid beta-peptide (Abeta) is a major factor in the etiology of Alzheimer's disease. beta-Secretase (BACE) initiates the generation of Abeta by cleaving the amyloid precursor protein at the beta-site and is therefore a prime target for therapeutic intervention.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'J Neurosci2005', '16306400'),\n",
       "   'evidence': \"Beta-secretase [beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1)] is the key rate-limiting enzyme for the production of the beta-amyloid (Abeta) peptide involved in the pathogenesis of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Anal Bioanal Chem2007', '17541560'),\n",
       "   'evidence': \"The amyloid beta (Abeta) peptide is responsible for toxic amyloid plaque formation and is central to the aetiology of Alzheimer's disease (AD).\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Non-amyloidogenic pathway'),\n",
       "   'citation': ('PubMed', 'PLoS One2013', '23577068'),\n",
       "   'evidence': 'PrP(C) decreases amyloid-beta (Abeta) production, which is involved in AD pathogenesis, by inhibiting beta-secretase (BACE1) activity.',\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  6,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',),\n",
       "   'citation': ('PubMed', 'Journal of Biological Chemistry1996', '8626687'),\n",
       "   'evidence': \"A beta is thought to play a role in the pathogenesis of Alzheimer's disease, and, hence, considerable effort has been invested in defining the means by which A beta is generated from the APPs.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  266,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway', 'ApoE pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'Neurobiol Aging. 2012 Mar;33(3):628.e1-628.e14. doi: 10.1016/j.neurobiolaging.2011.04.010. Epub 2011 Jun 15.',\n",
       "    '21676498'),\n",
       "   'evidence': \"Inheritance of the \\x83\\x824 allele of apolipoprotein E (ApoE) is the only confirmed and consistently replicated risk factor for late onset Alzheimer's disease (AD). ApoE is also a key ligand for low-density lipoprotein (LDL) receptor-related protein (LRP), a major neuronal low-density lipoprotein receptor. ApoE and LRP mRNA expression was significantly elevated in the postmortem inferior temporal gyrus (area 20) and the hippocampus from individuals with dementia compared with those with intact cognition. In addition to their strong association with the progression of cognitive dysfunction, LRP and ApoE mRNA levels were also positively correlated with increasing neuropathological hallmarks of AD. Additionally, Western blot analysis of ApoE protein expression in the hippocampus showed that the differential expression observed at the transcriptional level is also reflected at the protein level. Given the critical role played by LRP and ApoE in amyloid beta (A\\x83\\x82) and cholesterol trafficking, increased expression of LRP and ApoE may not only disrupt cholesterol homeostasis but may also contribute to some of the neurobiological features of AD, including plaque deposition.\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (7,\n",
       "  155,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'Response to oxidative stress pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurosci. 2006 May 10;26(19):5167-79',\n",
       "    '16687508'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (7,\n",
       "  155,\n",
       "  {'Subgraph': ('Amyloidogenic pathway',\n",
       "    'Response to oxidative stress pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Neurosci. 2006 May 10;26(19):5167-79',\n",
       "    '16687508'),\n",
       "   'evidence': \"Alzheimer's disease (AD) is associated with accumulations of amyloid-beta (Abeta) peptides, oxidative damage, mitochondrial dysfunction, neurodegeneration, and dementia\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  155,\n",
       "  {'Subgraph': ('Acetylcholine signaling pathway',),\n",
       "   'citation': ('Online Resource', 'AD_HBP', 'DB00989'),\n",
       "   'evidence': \"Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.\",\n",
       "   'rel': 'positiveCorrelation'}),\n",
       " (7,\n",
       "  155,\n",
       "  {'citation': ('PubMed', 'J Neurosci2009', '19458225'),\n",
       "   'evidence': \"The neuronal loss associated with Alzheimer's disease (AD) affects areas of the brain that are vital to cognition.\",\n",
       "   'rel': 'association'}),\n",
       " (7,\n",
       "  92,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Toxicol. 2012;2012:187297. Epub 2012 Feb 8.',\n",
       "    '22496686'),\n",
       "   'evidence': 'Role of LPR8 activation in normal brain functioning and in neurodegeneration during AD.',\n",
       "   'object_activity': 'act',\n",
       "   'rel': 'association'}),\n",
       " (1217,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Akt pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2010 Mar 19;285(12):8515-26. doi: 10.1074/jbc.M109.079079. Epub 2010 Jan 22.',\n",
       "    '20097758'),\n",
       "   'evidence': 'ATXN1 functions as a genetic risk modifier that contributes to AD pathogenesis through a loss-of-function mechanism by regulating beta-secretase cleavage of APP and Abeta levels.',\n",
       "   'rel': 'association'}),\n",
       " (1217,\n",
       "  3,\n",
       "  {'Subgraph': ('Beta secretase pathway', 'Akt pathway'),\n",
       "   'citation': ('PubMed', 'Nat Rev Neurol2010', '20139999'),\n",
       "   'evidence': 'Regarding the underlying molecular mechanism, we show that the effect of ATXN1 expression on Abeta levels is pmodulated via beta-secretase cleavage of APP. ',\n",
       "   'object_activity': 'pep',\n",
       "   'rel': 'decreases'}),\n",
       " (1217,\n",
       "  6,\n",
       "  {'Subgraph': ('Non-amyloidogenic pathway', 'Akt pathway'),\n",
       "   'citation': ('PubMed', 'Nat Rev Neurol2010', '20139999'),\n",
       "   'evidence': 'We show that knock-down of ATXN1 significantly increases the levels of both Abeta40 and Abeta42. This effect could be rescued with concurrent overexpression of ATXN1. Moreover, overexpression of ATXN1 decreased Abeta levels. ',\n",
       "   'rel': 'decreases'}),\n",
       " (2936, 2937, {'rel': 'product'}),\n",
       " (2937,\n",
       "  2937,\n",
       "  {'NervousSystem': ('Brain',),\n",
       "   'Subgraph': ('Amyloidogenic pathway', 'Endosomal lysosomal pathway'),\n",
       "   'citation': ('PubMed', 'J Alzheimers Dis. 2012;28(2):337-44', '22232000'),\n",
       "   'evidence': \"Clusterin, a multifunctional lipoprotein is expressed in a number of tissues but expression is particularly high in the brain, where it binds to amyloid-\\x83 (A\\x83), possibly facilitating A\\x83 transport into the bloodstream.Its concentration in peripheral blood was identified as a potential biomarker for Alzheimer's disease (AD).\",\n",
       "   'rel': 'directlyDecreases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'MESHCS',\n",
       "   'subject_translocation_from_value': 'Brain',\n",
       "   'subject_translocation_to_namespace': 'MESHCS',\n",
       "   'subject_translocation_to_value': 'Blood'}),\n",
       " (2937,\n",
       "  2937,\n",
       "  {'Subgraph': ('Low density lipoprotein pathway',\n",
       "    'Endosomal lysosomal pathway'),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2012 Mar 1. [Epub ahead of print]',\n",
       "    '22383525'),\n",
       "   'evidence': 'Cellular uptake and degradation by glial cells is one means by which A\\x83 may be cleared from the brain. In the current study, we demonstrate that modulating levels of the low-density lipoprotein receptor (LDLR), a cell surface receptor that regulates the amount of apolipoprotein E (apoE) in the brain, altered both the uptake and degradation of A\\x83 by astrocytes. Deletion of LDLR caused a decrease in A\\x83 uptake, while increasing LDLR levels significantly enhanced both the uptake and clearance of A\\x83. Increasing LDLR levels also enhanced the cellular degradation of A\\x83 and facilitated the vesicular transport of A\\x83 to lysosomes. Despite the fact that LDLR regulated the uptake of apoE by astrocytes, we found that the effect of LDLR on A\\x83 uptake and clearance occurred in the absence of apoE. Finally, we provide evidence that A\\x83 can directly bind to LDLR, suggesting an interaction between LDLR and A\\x83 could be responsible for LDLR-mediated A\\x83 uptake. Therefore, these results identify LDLR as a receptor that mediates A\\x83 uptake and clearance by astrocytes, and provide evidence that increasing glial LDLR levels may promote A\\x83 degradation within the brain',\n",
       "   'object_activity': 'deg',\n",
       "   'rel': 'increases',\n",
       "   'subject_translocation': True,\n",
       "   'subject_translocation_from_namespace': 'MESHCS',\n",
       "   'subject_translocation_from_value': 'COP-Coated Vesicles',\n",
       "   'subject_translocation_to_namespace': 'MESHCS',\n",
       "   'subject_translocation_to_value': 'Lysosomes'}),\n",
       " (2937,\n",
       "  7,\n",
       "  {'Subgraph': ('Nerve growth factor pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Neurochem Int. 2012 Dec;61(8):1289-93. doi: 10.1016/j.neuint.2012.09.005. Epub 2012 Sep 24.',\n",
       "    '23017601'),\n",
       "   'evidence': \"Amyloid  (A) aggregates are the primary component of senile plaques in Alzheimer disease (AD) patient's brain. A is known to bind p75 neurotrophin receptor (p75(NTR)) and mediates A-induced neuronal death. Recently, we showed that NGF leads to p75(NTR) polyubiquitination, which promotes neuronal cell survival. Here, we demonstrate that A stimulation impaired the p75(NTR) polyubiquitination. TRAF6 and p62 are required for polyubiquitination of p75(NTR) on NGF stimulation. Interestingly, we found that overexpression of TRAF6/p62 restored p75(NTR) polyubiquitination upon A/NGF treatment. A significantly reduced NF-B activity by attenuating the interaction of p75(NTR) with IKK. p75(NTR) increased NF-B activity by recruiting TRAF6/p62, which thereby mediated cell survival. These findings indicate that TRAF6/p62 abrogated the A-mediated inhibition of p75(NTR) polyubiquitination and restored neuronal cell survival.\",\n",
       "   'rel': 'increases'}),\n",
       " (2937,\n",
       "  7,\n",
       "  {'Cell': ('Astrocytes',),\n",
       "   'Subgraph': ('Sphingolipid metabolic pathway',),\n",
       "   'citation': ('PubMed',\n",
       "    'Eur J Neurosci. 2007 Oct;26(8):2131-41. Epub 2007 Oct 1.',\n",
       "    '17908174'),\n",
       "   'evidence': \"We found that palmitic acid significantly increased de-novo synthesis of ceramide in astroglia, which/ in turn was involved in inducing both increased production of the Abeta protein and hyperphosphorylation of the tau/ protein. Increased amyloidogenesis and hyperphoshorylation of tau lead to formation of the two most important/ pathophysiological characteristics associated with AD, Abeta or senile plaques and neurofibrillary tangles, respectively./ In addition to these pathophysiological changes, AD is also characterized by certain metabolic changes; abnormal/ cerebral glucose metabolism is one of the distinct characteristics of AD. In this context, we found that palmitic/ acid significantly decreased the levels of astroglial glucose transporter (GLUT1) and down-regulated glucose uptake/ and lactate release by astroglia. Our present data establish an underlying mechanism by which saturated fatty acids/ induce AD-associated pathophysiological as well as metabolic changes, placing 'astroglial fatty acid metabolism' at/ the center of the pathogenic cascade in AD.\",\n",
       "   'rel': 'increases'}),\n",
       " (11457, 2937, {'rel': 'product'}),\n",
       " (1534, 1537, {'rel': 'in_list'}),\n",
       " (1534,\n",
       "  6,\n",
       "  {'Subgraph': ('Notch pathway',\n",
       "    'Non-amyloidogenic pathway',\n",
       "    'Gamma secretase pathway'),\n",
       "   'UserdefinedSpecies': ('C elegans',),\n",
       "   'citation': ('PubMed',\n",
       "    'J Biol Chem. 2003 May 30;278(22):20117-23. Epub 2003 Mar 14.',\n",
       "    '12639958'),\n",
       "   'evidence': \"PEN-2 is an integral membrane protein that is a necessary component of the gamma-secretase complex, which is central in the pathogenesis of Alzheimer's disease and is also required for Notch signaling. In the absence of PEN-2, Notch signaling fails to guide normal development in Caenorhabditis elegans, and amyloid beta peptide is not generated from the amyloid precursor protein\",\n",
       "   'rel': 'decreases',\n",
       "   'subject_activity': 'deg'})]"
      ]
     },
     "execution_count": 113,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "graph_100.edges(data=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Task 4: Find shortest paths between all nodes link to the edges found in the previsious task and create a new graph, display it"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 137,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAeIAAAFBCAYAAACrYazjAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nSUVORK5CYII=\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x10e369860>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "nx.draw(AD_subgraph, with_labels=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "metadata": {
    "collapsed": false,
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{2: {2: [2],\n",
       "  3: [2, 7, 3],\n",
       "  4: [2, 7, 3, 4],\n",
       "  5: [2, 7, 3, 5],\n",
       "  6: [2, 7, 3, 6],\n",
       "  7: [2, 7],\n",
       "  2212: [2, 2212]},\n",
       " 3: {2: [3, 7, 2],\n",
       "  3: [3],\n",
       "  4: [3, 4],\n",
       "  5: [3, 5],\n",
       "  6: [3, 6],\n",
       "  7: [3, 7],\n",
       "  2212: [3, 7, 2, 2212]},\n",
       " 4: {4: [4]},\n",
       " 5: {2: [5, 3, 7, 2],\n",
       "  3: [5, 3],\n",
       "  4: [5, 3, 4],\n",
       "  5: [5],\n",
       "  6: [5, 3, 6],\n",
       "  7: [5, 3, 7],\n",
       "  2212: [5, 3, 7, 2, 2212]},\n",
       " 6: {2: [6, 7, 2],\n",
       "  3: [6, 3],\n",
       "  4: [6, 3, 4],\n",
       "  5: [6, 3, 5],\n",
       "  6: [6],\n",
       "  7: [6, 7],\n",
       "  2212: [6, 7, 2, 2212]},\n",
       " 7: {2: [7, 2],\n",
       "  3: [7, 3],\n",
       "  4: [7, 3, 4],\n",
       "  5: [7, 3, 5],\n",
       "  6: [7, 3, 6],\n",
       "  7: [7],\n",
       "  2212: [7, 2, 2212]},\n",
       " 2212: {2: [2212, 2],\n",
       "  3: [2212, 2, 7, 3],\n",
       "  4: [2212, 2, 7, 3, 4],\n",
       "  5: [2212, 2, 7, 3, 5],\n",
       "  6: [2212, 2, 7, 3, 6],\n",
       "  7: [2212, 2, 7],\n",
       "  2212: [2212]}}"
      ]
     },
     "execution_count": 132,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "lst_edges_AD = find_edges_by_attrib_key_value(graph_100, 'MeSHDisease', 'Alzheimer Disease')\n",
    "AD_subgraph = nx.MultiDiGraph()\n",
    "AD_subgraph.add_edges_from(lst_edges_AD)\n",
    "# # nx.shortest_path(graph_100, )\n",
    "nx.shortest_path(AD_subgraph)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.5.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
